<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id><journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id><journal-id journal-id-type="hwp">nar</journal-id><journal-id journal-id-type="publisher-id">nar</journal-id><journal-title-group><journal-title>Nucleic Acids Research</journal-title></journal-title-group><issn pub-type="ppub">0305-1048</issn><issn pub-type="epub">1362-4962</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4889949</article-id><article-id pub-id-type="doi">10.1093/nar/gkw282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Survey and Summary</subject></subj-group></article-categories><title-group><article-title>Discovering and understanding oncogenic gene fusions through data intensive computational approaches</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Latysheva</surname><given-names>Natasha S.</given-names></name><xref ref-type="corresp" rid="COR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Babu</surname><given-names>M. Madan</given-names></name><xref ref-type="corresp" rid="COR2">*</xref></contrib><aff id="AFF1">MRC Laboratory of Molecular Biology, Francis Crick Ave, Cambridge CB2 0QH, United Kingdom</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label>To whom correspondence should be addressed. Tel: +44 1223 267834; Fax: +44 1223 213556; Email: <email>natashal@mrc-lmb.cam.ac.uk</email></corresp><corresp id="COR2">Correspondence may also be addressed to M. Madan Babu. Tel: +44 1223 267066; Fax: +44 1223 268300; Email: <email>madanm@mrc-lmb.cam.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>02</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>21</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>4</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the							<pub-date pub-type="epub"/>. --><volume>44</volume><issue>10</issue><fpage>4487</fpage><lpage>4503</lpage><history><date date-type="accepted"><day>24</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2016</year></date><date date-type="received"><day>12</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="gkw282.pdf"/><abstract><p>Although gene fusions have been recognized as important drivers of cancer for decades, our understanding of the prevalence and function of gene fusions has been revolutionized by the rise of next-generation sequencing, advances in bioinformatics theory and an increasing capacity for large-scale computational biology. The computational work on gene fusions has been vastly diverse, and the present state of the literature is fragmented. It will be fruitful to merge three camps of gene fusion bioinformatics that appear to rarely cross over: (i) data-intensive computational work characterizing the molecular biology of gene fusions; (ii) development research on fusion detection tools, candidate fusion prioritization algorithms and dedicated fusion databases and (iii) clinical research that seeks to either therapeutically target fusion transcripts and proteins or leverages advances in detection tools to perform large-scale surveys of gene fusion landscapes in specific cancer types. In this review, we unify these different&#x02014;yet highly complementary and symbiotic&#x02014;approaches with the view that increased synergy will catalyze advancements in gene fusion identification, characterization and significance evaluation.</p></abstract><counts><page-count count="17"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>02 June 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="SEC1"><title>INTRODUCTION</title><p>Gene fusions are hybrid genes formed when two previously independent genes become juxtaposed. The fusion can result from structural rearrangements like translocations and deletions, transcription read-through of neighboring genes (<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>), or the <italic>trans</italic>- and <italic>cis</italic>-splicing of pre-mRNAs (<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>). Many gene fusions are associated with oncogenic properties, and often act as driver mutations in a wide array of cancer types (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>). Gene fusions commonly exert their oncogenic influence by either deregulating one of the involved genes (e.g. by fusing a strong promoter to a proto-oncogene), forming a fusion protein with oncogenic functionality (e.g. by causing a constitutive activation of a tyrosine kinase) or inducing a loss of function (e.g. by truncating a tumor suppressor gene). One estimate states that translocations and gene fusions are responsible for 20% of global cancer morbidity (<xref rid="B11" ref-type="bibr">11</xref>), largely due to their central involvement in prostate cancer. Recent bioinformatics advances have elucidated many aspects of oncogenic gene fusions, from the origin and causative importance of fusion events, to the structural and regulatory properties of fusion proteins.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Mechanisms of gene fusion formation. (<bold>A</bold>) Structural rearrangements of chromosomes, such as translocations, inversions, deletions and insertions, can lead to the formation of gene fusions. These hybrid genes may then be transcribed and translated into fusion transcripts and proteins. (<bold>B</bold>) Non-structural rearrangement&#x000a0;mechanisms, such as transcription read-through of neighboring genes or splicing of mRNA molecules, are increasingly recognized as leading to the formation of a large proportion of gene fusions.</p></caption><graphic xlink:href="gkw282fig1"/></fig><p>The total number of gene fusions is now estimated to be 10 000, with over 90% of these being identified in the past 5 years due to advances in deep-sequencing and fusion detection algorithms (<xref rid="B12" ref-type="bibr">12</xref>). The prevalence of gene fusions varies widely between cancer types (<xref rid="B10" ref-type="bibr">10</xref>): at one extreme, gene fusions occur in (and frequently drive) 90% of all lymphomas, over half of leukemias (<xref rid="B13" ref-type="bibr">13</xref>), and one third of soft tissue tumors (<xref rid="B14" ref-type="bibr">14</xref>). In prostate cancer, one specific fusion (<italic>TMPRSS2-ERG</italic>) is the most common genetic alteration, being found in over 50% of patients (<xref rid="B15" ref-type="bibr">15</xref>). However, many recurrent gene fusions occur at low frequencies, such as the <italic>KIF5B-RET</italic> fusion, which is present in 1&#x02013;2% of lung adenocarcinomas (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>Knowledge of both common and rare gene fusions has improved numerous aspects of clinical care. For example, the <italic>TMPRSS2-ERG</italic> fusion transcript functions as a urinary biomarker for prostate cancer risk and prognosis (<xref rid="B17" ref-type="bibr">17</xref>) and gene fusions are used in the diagnosis of a variety of cancers (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>). Gene fusions have also been important in identifying molecular subtypes of cancers (<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>), patient stratification (<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>), monitoring residual disease post-treatment (<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>) and predicting relapse (<xref rid="B25" ref-type="bibr">25</xref>). Importantly, fusion transcripts are also promising therapeutic targets (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B26" ref-type="bibr">26</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>). As an example, the development of drugs that target the ATP-binding sites (<xref rid="B29" ref-type="bibr">29</xref>) and allosteric regions (<xref rid="B30" ref-type="bibr">30</xref>) of the <italic>BCR-ABL</italic> fusion kinase, a constitutively active tyrosine kinase and the driving mutation in chronic myelogenous leukemia, has significantly improved patient outcome. Similarly, inhibitors of the anaplastic lymphoma kinase (ALK) protein have greatly improved prospects for patients with <italic>EML4-ALK</italic> fusion positive non-small cell lung tumors (<xref rid="B31" ref-type="bibr">31</xref>).</p><p>Although fusions have been recognized drivers of cancer for over 30 years, recent bioinformatics studies have substantially enriched our knowledge of fusions. However, the computational gene fusion literature is dispersed&#x02014;for example, many fusion landscape studies make little reference to bioinformatics surveys of gene fusion molecular biology, which could help elucidate the function of novel fusions and set them into the context of other known oncogenic fusions. Similarly, an increased awareness of fusion prioritization algorithms could aid investigators in narrowing down putative fusion lists to only the instances that are likely to be biologically functional. This review aims to promote increased exposure and collaboration between different gene fusion researchers, especially those involved in identifying and describing novel fusions. In <bold>Section 1</bold>, we discuss the findings of recent data-intensive computational methods to study global properties of gene fusions, including gene fusion landscapes across different cancer types and the structural and regulatory characteristics of fusion proteins. In <bold>Section 2</bold>, we briefly outline fusion detection tools before focusing on reviewing computational approaches for prioritizing driver fusions and efforts to catalog and annotate oncogenic gene fusions within specialized databases.</p></sec><sec id="SEC2"><title>DATA-INTENSIVE COMPUTATIONAL STUDIES OF GENE FUSION FUNCTIONALITY</title><p>Bioinformatics approaches have been crucial to identifying global patterns in gene fusion functionality. In this section, we outline the recent computational work on the molecular functions, structural design principles and regulatory features of fusion proteins across diverse cancers.</p><sec id="SEC2-1"><title>Global trends in gene fusion formation and function</title><p>Gene fusion landscapes have now been studied in many cancer types, including breast (<xref rid="B32" ref-type="bibr">32</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>), lung (<xref rid="B35" ref-type="bibr">35</xref>), prostate (<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>), lymphoid (<xref rid="B40" ref-type="bibr">40</xref>), soft tissue (<xref rid="B14" ref-type="bibr">14</xref>) and gastric cancer (<xref rid="B3" ref-type="bibr">3</xref>) (see (<xref rid="B19" ref-type="bibr">19</xref>) for a collection of fusion landscape studies in epithelial cancers). Such studies have generated diverse insights, such as the finding that gene fusions are the major genomic abnormality in glioblastoma multiforme (<xref rid="B41" ref-type="bibr">41</xref>) and the discovery that private gene fusions cause an aggressive type of prostate cancer (<xref rid="B42" ref-type="bibr">42</xref>). The biology of certain rare cancers has been elucidated by the discovery of frequent oncogenic fusions, including the <italic>C11orf95-RELA</italic> fusion in supratentorial ependymoma (<xref rid="B43" ref-type="bibr">43</xref>) and the recurrent <italic>DNAJB1-PRKACA</italic> fusion in fibrolamellar hepatocellular carcinoma (<xref rid="B44" ref-type="bibr">44</xref>). These large-scale surveys continue to underscore the importance of screening for gene fusions (Figure <xref ref-type="fig" rid="F2">2A</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Trends in fusion functionality. (<bold>A</bold>) Recent surveys have uncovered the diverse gene fusion landscapes present in a variety of cancers. (<bold>B</bold>) The frequency of gene fusions varies by cancer type and appears to anti-correlate with frequencies of other somatic mutations at the level of both cancer types and individual tumor samples. (<bold>C</bold>) Gene fusions tend to involve genes with kinase, DNA-binding and chromatin modifying activity. (<bold>D</bold>) Network studies of fusions have identified global and cancer-type-specific patterns in gene partnerships, such as the trend toward most fusion genes only fusing with only one other partner.</p></caption><graphic xlink:href="gkw282fig2"/></fig><p>Given the expanding list of known gene fusions in cancer, it is important to understand the types of genes that frequently form fusions and what partners they fuse with. Gene fusion networks, in which nodes are individual genes and edges indicate the occurrence of a fusion between those genes, offer an organized approach to studying fusion partnerships (Figure <xref ref-type="fig" rid="F2">2B</xref>). Several studies of gene fusion networks have found that the majority of fusion genes partner with a single other gene, with only a few genes being highly promiscuous (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B45" ref-type="bibr">45</xref>&#x02013;<xref rid="B47" ref-type="bibr">47</xref>). An extreme example of promiscuity is the mixed lineage leukemia (<italic>MLL</italic>) gene, which fuses with over 60 different partner genes, and causes most infant leukemias and a significant proportion of adult leukemias (<xref rid="B48" ref-type="bibr">48</xref>). The set of fusion partners for a given gene may be influenced by the position of those partners in protein interaction networks (<xref rid="B49" ref-type="bibr">49</xref>), their domain content (<xref rid="B46" ref-type="bibr">46</xref>) or their structural capabilities (e.g. oligomerization ability in <italic>FGFR</italic> fusion partners (<xref rid="B50" ref-type="bibr">50</xref>)), but these concepts require further investigation. H&#x000f6;glund <italic>et&#x000a0;al</italic>. performed the pioneering work on gene fusion networks using 291 oncogenic gene fusions from the Mitelman database (<xref rid="B45" ref-type="bibr">45</xref>). In addition to demonstrating that most fusion genes form few fusions, the fusion network was found to be fragmented-fusion pairs from hematological, mesenchymal and epithelial tumors tended to localize to different sections of the network, suggesting that gene fusion pairs are segregated according to tumor histology. However, this type of fragmentation in gene fusion networks may have been due to incomplete knowledge&#x02014;in an updated gene fusion network analysis with 358 gene fusion pairs (<xref rid="B11" ref-type="bibr">11</xref>), 89% of genes formed three large interconnected networks, compared to 72% in the previous study. This updated gene fusion network study confirmed both the presence of several highly promiscuous fusion genes (e.g. <italic>MLL, ETV6, EWSR1</italic>) and many poorly connected ones, and also the apparent grouping of the network by cancer type (<xref rid="B11" ref-type="bibr">11</xref>). Interestingly, gene fusion networks can differ substantially in their topology across different cancer types&#x02014;for example, the gene fusion network in acute myelogenous leukemia is clustered around a few genes (like <italic>MLL</italic> and <italic>NUP98</italic>), whereas the ovarian cancer gene fusion network is much more dispersed, with very few genes fusing with more than one partner (<xref rid="B12" ref-type="bibr">12</xref>). The basis for these cancer subtype-specific differences in gene fusion networks remains to be explained.</p><p>Several bioinformatics studies have searched for trends in fusion frequencies across cancers (Figure <xref ref-type="fig" rid="F2">2C</xref>). In general, the frequency of recurrent fusion transcripts is much lower than other somatic mutations (<xref rid="B51" ref-type="bibr">51</xref>). For example, in lung adenocarcinoma, the <italic>EML4-ALK</italic> driver fusion occurs at a rate of 6%, while driver mutations in <italic>KRAS</italic> and <italic>EGFR</italic> are much more common (rates of 25 and 23%, respectively) (<xref rid="B52" ref-type="bibr">52</xref>). Furthermore, the rates of gene fusions vary significantly across cancer types (<xref rid="B11" ref-type="bibr">11</xref>). A recent bioinformatics survey of gene fusions in TCGA identified 7887 high confidence fusion transcripts, with substantial differences in fusion frequencies across tumor types (highest rates in bladder cancers and the lowest in thyroid carcinoma) (<xref rid="B10" ref-type="bibr">10</xref>). Interestingly, the same study discovered a significant anti-correlation between frequencies of recurrent in-frame fusion transcripts and other gene mutations, hinting at potential oncogenic redundancy. However, given that in most tumors, &#x0003e;80% of fusion transcripts were associated with genomic instability (DNA amplification or deletion), it is unclear what proportion of gene fusions are oncogenic drivers rather than instability-induced passengers. The association between genomic instability and gene fusions has been previously reported (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B53" ref-type="bibr">53</xref>), and it has been suggested that non-recurrent, singleton gene fusions are potential passenger mutations (<xref rid="B54" ref-type="bibr">54</xref>).</p><p>One open question concerns whether gene fusions play similar roles in different cancer types (Figure <xref ref-type="fig" rid="F2">2D</xref>). There are some hints that gene fusions in carcinomas are more likely to disrupt cell signaling processes involved in cell proliferation and homeostasis (<xref rid="B55" ref-type="bibr">55</xref>) than in hematopoietic and mesenchymal cancers, possibly due to differences in differentiation history. However, the same broad categories of genes tend to be fused in all cancers&#x02014;predominantly, kinases and transcriptional control genes (<xref rid="B56" ref-type="bibr">56</xref>). Fusions involving kinases have been extensively documented as an important class of gene fusions (<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B57" ref-type="bibr">57</xref>) and are especially interesting due to their susceptibility to kinase inhibitors (<xref rid="B58" ref-type="bibr">58</xref>). Recently, at least one in-frame kinase fusion was found in 7.4% of analysed tumor samples in TCGA, with the highest rates occurring in thyroid carcinoma. This suggests that kinase inhibition will continue to grow as a promising treatment option for kinase fusion-positive cancers (<xref rid="B10" ref-type="bibr">10</xref>). Another study of kinase fusions also reported the highest rate of recurrent kinase fusions in thyroid cancers, and further found that fusions between the kinases <italic>ALK, BRAF, MET, NTRK1, NTRK2, RAF1</italic> and <italic>RET</italic> were mutually exclusive (<xref rid="B54" ref-type="bibr">54</xref>). Histone methyltransferases are increasingly recognized as another attractive drug target in cancer (<xref rid="B59" ref-type="bibr">59</xref>), and were found to be fused in-frame in 2.5% of all tumor samples in TCGA in a mutually exclusive manner with protein kinase fusions (<xref rid="B10" ref-type="bibr">10</xref>). Finding the rationale behind observed patterns of mutual exclusivity between gene fusions and other oncogenic mutations, as well as between different types of gene fusions, is likely to be a fruitful avenue for future research.</p><p>Many gene fusions are found across a variety of different cancer types. For example, <italic>RAF</italic> kinase family fusions have recently been profiled across a dozen different solid tumors (<xref rid="B60" ref-type="bibr">60</xref>), and FGFR tyrosine kinase fusion proteins (which interestingly, occasionally exclude the tyrosine kinase domain) are similarly promiscuous (<xref rid="B50" ref-type="bibr">50</xref>). In such cases, treatments developed for a specific cancer type can potentially be used to treat another. For instance, FGFR fusion proteins have emerged as promising therapeutic targets across the spectrum of cancers they are detected in (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B61" ref-type="bibr">61</xref>&#x02013;<xref rid="B64" ref-type="bibr">64</xref>). A growing number of studies seek to target oncogenic fusion transcripts and proteins, and an overview of recent therapeutic work has recently been written (<xref rid="B19" ref-type="bibr">19</xref>), together with a compiled list of 33 recent clinical trials targeting epithelial cancer fusions (Additional File 2 within reference). Fusions involving the <italic>ALK, ETS</italic> and <italic>RET</italic> genes dominate this list (<xref rid="B19" ref-type="bibr">19</xref>), suggesting that updates to the treatment repertoires of the cancers affected by these fusions are forthcoming.</p><p>Knowledge of how precisely fusion transcripts or proteins have been successfully targeted will be valuable for future drug development studies. One important success story is the treatment of non-small-cell lung cancer with ALK inhibitors (<xref rid="B65" ref-type="bibr">65</xref>). The transforming <italic>EML4-ALK</italic> fusion transcript was initially detected in approximately 7% of patients with non-small-cell lung cancer (NSCLC) (<xref rid="B66" ref-type="bibr">66</xref>), with the fusion being mutually exclusive with the better-known <italic>EGFR</italic> mutations. The EML4-ALK fusion protein consists of the N-terminus of the microtubule-associated EML4 protein and the C-terminus of the ALK receptor tyrosine kinase, which itself contains an intact tyrosine kinase domain that mediates ALK oligomerization and the subsequent induction of constitutive kinase activity. Similarly to many other fusions, the tyrosine kinase domain of ALK was from the start found to be core to the oncogenic activity of the EML4<italic>-</italic>ALK fusion protein (<xref rid="B66" ref-type="bibr">66</xref>). Highly effective and well-tolerated ALK inhibitors, such as crizotinib, were rapidly developed for therapeutic purposes (<xref rid="B65" ref-type="bibr">65</xref>,<xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B69" ref-type="bibr">69</xref>). Crizotinib inhibits the ALK tyrosine kinase by binding to its ATP-binding pocket, and the introduction of this drug substantially improved prospects in both <italic>EML4-ALK</italic> positive (<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B65" ref-type="bibr">65</xref>) and <italic>ROS1</italic> fusion positive NSCLC patients (<xref rid="B70" ref-type="bibr">70</xref>,<xref rid="B71" ref-type="bibr">71</xref>). However, through a variety of mechanisms (<xref rid="B72" ref-type="bibr">72</xref>&#x02013;<xref rid="B76" ref-type="bibr">76</xref>), both <italic>ALK</italic> and <italic>ROS1</italic> fusion positive NSCLC are susceptible to developing resistance to crizotinib, and current research focuses on overcoming this resistance (<xref rid="B77" ref-type="bibr">77</xref>&#x02013;<xref rid="B79" ref-type="bibr">79</xref>). The prevalence of gene fusions involving kinases (<xref rid="B54" ref-type="bibr">54</xref>) such as <italic>ALK</italic> (<xref rid="B80" ref-type="bibr">80</xref>,<xref rid="B81" ref-type="bibr">81</xref>), together with the relatively high success of targeting kinases in cancer (<xref rid="B82" ref-type="bibr">82</xref>), suggest that research focusing on inhibiting deregulated fusion kinases will continue to pay dividends. Notably, nuanced knowledge of the specific structural variants of the same type of fusion protein (<xref rid="B33" ref-type="bibr">33</xref>) and the downstream signaling of fusion proteins (<xref rid="B83" ref-type="bibr">83</xref>) can be key to developing successful therapeutic agents, reinforcing the need for larger scale computational studies which can detect these molecular trends and suggest candidate targets.</p></sec><sec id="SEC2-2"><title>Structural properties of fusion proteins</title><p>Fusion transcripts can be translated into fusion proteins, though estimates of translation frequency vary (<xref rid="B84" ref-type="bibr">84</xref>). Predicting the function of fusion products is non-trivial, but is distinct from the extremely difficult task of predicting a protein's function from a sequence. One can attempt to infer a fusion protein's function by examining the structural and regulatory features of the parent proteins it is composed of, as well as the precise segments of the parent proteins that form the fusion product. A variety of studies have tried to understand the underlying structural design principles of fusion proteins by examining translocation breakpoint positions, domain architectures and the role of intrinsic structural disorder.</p><p>The location of translocation breakpoints in cancer is known to be non-random and recurrent, and has been extensively demonstrated to be influenced by both the spatial proximity of chromosomes in the nucleus as well as features of the DNA sequence, such as repeats, fragile sites and endonuclease misrecognition sites (<xref rid="B85" ref-type="bibr">85</xref>) (Figure <xref ref-type="fig" rid="F3">3A</xref>). However, the structure and function of the resulting fusion proteins has emerged as an additional force governing breakpoint locations. For example, one global analysis of fusion transcripts reported that translocation breakpoint positions almost universally (98%) conserve reading-frame compatibility (<xref rid="B46" ref-type="bibr">46</xref>). However, the most recent census of fusions across 13 tumor types reported that 36% of detected fusion transcripts are in frame, with AML and thyroid carcinoma having the highest rates of reading frame conservation (79 and 70%, respectively) (<xref rid="B10" ref-type="bibr">10</xref>). Interestingly, these were also the cancer types with the highest rates of balanced translocations. More recently, a study aimed at discovering novel gene fusions in prostate cancer found a very limited number of feasible transcripts, and most were not in frame (<xref rid="B36" ref-type="bibr">36</xref>). A fusion prioritization study found that in-frame transcripts were the most powerful predictor of driver fusions (<xref rid="B86" ref-type="bibr">86</xref>), confirming the intuition that in-frame transcripts are crucial to function. These conflicting reports appear to suggest that rates of reading frame conservation&#x02014;which is likely to correlate with rates of functional and potentially driving gene fusions&#x02014;may vary significantly across cancer types and samples.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Structural features of fusion proteins. (<bold>A</bold>) Genes which form fusions tend to have fewer domains, but fusion transcript sequences have been shown to have more domains than expected by chance. (<bold>B</bold>) Fusion proteins are enriched for specific domains and permutations, which are occasionally proteomically novel. (<bold>C</bold>) Fusion breakpoints are biased toward locations which preserve fusion protein reading frames and structural viability. <bold>(D)</bold> Increased intrinsic disorder in fusion proteins may permit the protein to fold and place the constituent domains into proximity of each other.</p></caption><graphic xlink:href="gkw282fig3"/></fig><p>Translocation breakpoints have been found to generally occur in intrinsically disordered regions, which may reflect a selection for regions that can more seamlessly combine different segments (<xref rid="B87" ref-type="bibr">87</xref>) (Figure <xref ref-type="fig" rid="F3">3A</xref>). Notably, breakpoints were also observed to preferentially avoid splitting domains, and in instances where globular domains were split, the truncations tended to generate viable proteins due to the breakpoints being positioned in low hydrophobicity regions. Together with frame-shift conservation (where it occurs), such trends could reflect a selection on fusion proteins to maintain viability and evade degradation pathways.</p><p>A study of intrinsic disorder in fusion proteins found that translocated proteins are more intrinsically disordered and tend to have fewer Pfam domains than non-translocated proteins (<xref rid="B87" ref-type="bibr">87</xref>) (Figure <xref ref-type="fig" rid="F3">3B</xref>), which has recently been demonstrated again (<xref rid="B88" ref-type="bibr">88</xref>). However, another survey of fusion proteins showed that they contain complete protein domains much more frequently than would be expected if fusion transcripts were generated from randomly fused protein coding sequences (<xref rid="B89" ref-type="bibr">89</xref>). Hence, domains may be relatively rare in fusion proteins but occur more often than random. Where fully functional domains are present in fusion proteins, these could in some cases compete with original proteins and produce dominant negative effects&#x02014;for example, in their fusion protein set (<xref rid="B89" ref-type="bibr">89</xref>), DNA binding domains were found to be frequent but transcriptional activation domains were rare, which reflects a known dominant negative mechanism employed by some oncogenic fusion proteins (<xref rid="B90" ref-type="bibr">90</xref>). In general, fusions involving transcriptional activators or repressors could be liable to exerting dominant negative effects (<xref rid="B89" ref-type="bibr">89</xref>), and one of the best studied examples of this mechanism is the RUNX1-ETO fusion protein, which is implicated in the development of acute myeloid leukemia (<xref rid="B91" ref-type="bibr">91</xref>&#x02013;<xref rid="B93" ref-type="bibr">93</xref>). RUNX1-ETO exerts a dominant negative influence over RUNX1, a crucial regulator of hematopoietic stem cell differentiation, by interfering with normal RUNX1 function and blocking differentiation. The fusion proteins typically retain the DNA-binding Runt homology domain from the RUNX1 transcription factor, thus inheriting the ability to bind to RUNX1 target genes, as well as incorporating most of the transcriptional repressor ETO protein, thereby allowing the fusion protein to act as a constitutive transcriptional repressor through several mechanisms. The result is the transcriptional repression of RUNX1 target genes, which is strongly implicated in leukemogenesis (<xref rid="B91" ref-type="bibr">91</xref>).</p><p>The types of domain combinations observed in fusion proteins have been relatively well studied (Figure <xref ref-type="fig" rid="F3">3C</xref>). A survey of fusion protein domain architectures demonstrated that the same architectures are reused in different gene fusion events, providing an underlying principle behind fusion networks (<xref rid="B46" ref-type="bibr">46</xref>). The most commonly reused architectures in fusion proteins involve tyrosine kinases, EWS activation domains and Runt domains. In general, domain combinations with closer links to oncogenic behavior are more frequently found (<xref rid="B46" ref-type="bibr">46</xref>). Another study compared Pfam domain permutations in 7424 fusion mRNAs to domains in known human proteins (<xref rid="B89" ref-type="bibr">89</xref>) and reported that although most domain types (69%) appear in fusion proteins, eight domain types are over-represented. These included AT hooks (involved in transcriptional regulation) and MHC and receptor tyrosine kinase catalytic domains (which are membrane protein and receptor domains). Interestingly, some fusion proteins encode novel combinations of domains not found in normal proteins, including pairings between DNA-binding HLH (helix-loop-helix) and GTP-binding domains as well as fusions between PHD-zinc finger and coiled-coil (DNA binding) domains (<xref rid="B89" ref-type="bibr">89</xref>). However, novel domain recombinations may be rare&#x02014;fusions have been shown to preferentially include partners that, when fused, reconstitute known domain co-occurrences (<xref rid="B49" ref-type="bibr">49</xref>). Finally, a study of fusion protein exon and domain organization showed an enrichment of transmembrane domains and signal peptides in fusion proteins (<xref rid="B84" ref-type="bibr">84</xref>), which suggests that fusion protein functionality could be modulated by changing the cellular localization or context of biochemical functions.</p><p>In line with these findings, the presence of certain domains in fusion proteins has been shown to be predictive of driver fusions: the developers of the ConSig algorithm for fusion driver prioritization found that although domain architectures of fusion proteins were highly diverse, especially for 5&#x02032; partners, certain architectures were predictive of driver fusions (<xref rid="B49" ref-type="bibr">49</xref>). Interestingly, domain architectures did not appear to be significantly shared by sets of fusion partners of a given gene&#x02014;that is, there was no evidence that recombination patterns of specific fusion partners were especially impacted by domain content. Furthermore, there was no apparent association between specific domain architectures and tumor types. However, other reports have found evidence for different domain patterns in partner sets and across cancer types (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). Further work is required to reconcile the apparent conflict (which may be due to differences in datasets) and develop a molecular model for observed fusion partnerships.</p><p>Gene fusions are formed from two partner genes, and these partners need not necessarily encode similar structural elements. A computational study of domains and protein&#x02013;protein interaction (PPI) interfaces in fusion proteins found substantial differences in the structural properties of 5&#x02032; and 3&#x02032; fusion partner genes (<xref rid="B47" ref-type="bibr">47</xref>). Although both DNA-binding and PPI domains were most common in both 5&#x02032; and 3&#x02032; partners, kinase and histone modification domains were almost entirely absent in 3&#x02032; partners. The co-occurrence of domains in 5&#x02032; and 3&#x02032; partners is strongly correlated&#x02014;for example, protein interaction domains disproportionately co-occur with DNA-binding and kinase domains, which is a combination that could conceivably lead to signaling defects (<xref rid="B94" ref-type="bibr">94</xref>). The retention patterns also differ between 5&#x02032; and 3&#x02032; partners: the 3&#x02032; partners tended to retain a significant portion of their domains and protein interaction interfaces, whereas the 5&#x02032; partners tended to lose domains, often retained no domains and in the instances where they did retain domains, these tended to lack a clear oncogenic function. The Oncofuse predictor for prioritizing driver fusions found that lost interaction interfaces were actually more predictive of drivers than retained ones, hinting at the importance of loss of parental protein function effects, in addition to gain of function effects (<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B95" ref-type="bibr">95</xref>). Still, the protein interactions of fusion proteins are likely to contribute to oncogenicity, as suggested by the observation that, in known fusion partners, there is a significant over-representation of domain&#x02013;domain interactions among their constituent domains (<xref rid="B49" ref-type="bibr">49</xref>). These initial observations, as well as the recent successes in studying cancer mutations from the point of view of interaction networks (<xref rid="B96" ref-type="bibr">96</xref>&#x02013;<xref rid="B102" ref-type="bibr">102</xref>), call for deeper analyses of fusion&#x02013;protein interactions.</p><p>In addition to structured protein regions like domains, intrinsically disordered regions have been increasingly recognized as important functional players in the proteome and in disease (<xref rid="B103" ref-type="bibr">103</xref>,<xref rid="B104" ref-type="bibr">104</xref>) (Figure <xref ref-type="fig" rid="F3">3D</xref>). An early computational study found that translocated proteins are over twice as disordered as other human proteins, and this disorder may help mediate oncogenic functions by providing the flexibility necessary to allow the different elements in fusion proteins to synergistically interact (<xref rid="B87" ref-type="bibr">87</xref>).</p><p>Long non-coding RNAs (lncRNAs), which do not encode for proteins, have recently been the subject of interest in cancer research (<xref rid="B105" ref-type="bibr">105</xref>&#x02013;<xref rid="B107" ref-type="bibr">107</xref>). However, possibly due to the fact that many fusion-detection pipelines filter out fusion candidates that do not map to protein-coding regions, only a handful of gene fusions involving lncRNAs have been documented. The list includes a fusion between <italic>ETV1</italic> and a prostate-specific lncRNA in prostate cancer (<xref rid="B108" ref-type="bibr">108</xref>,<xref rid="B109" ref-type="bibr">109</xref>) and the fusion of the <italic>BCL6</italic> proto-oncogene with the non-coding <italic>GAS5</italic> gene in a B-cell lymphoma patient (<xref rid="B110" ref-type="bibr">110</xref>). These lncRNAs may simply contribute to the aberrant regulation of their oncogene partner, rather than having an oncogenic function themselves (<xref rid="B111" ref-type="bibr">111</xref>). Additionally, a study of prostate cancer in Asian populations found several novel fusions involving lncRNAs (<xref rid="B112" ref-type="bibr">112</xref>), including a surprisingly common gene fusion between the <italic>USP9Y</italic> protease and the <italic>TTTY15</italic> ncRNA, which results in a fusion transcript and is associated with a loss of <italic>USP9Y</italic> function. This fusion has since been found to be an effective urine-based biomarker that is predictive of prostate biopsy outcomes (<xref rid="B113" ref-type="bibr">113</xref>). These few cases highlight the fact that fusions involving lncRNAs can be functional and even clinically relevant, and therefore the current approach of filtering out non-coding gene fusions may be systematically omitting substantial useful information.</p><p>To conclude, the previous bioinformatic studies of the structural aspects of fusion proteins suggest the following trends: fusion proteins are structurally diverse, but tend to be disordered and depleted in domains. However, certain domain combinations are enriched, such as those involving kinase and DNA-binding activity. Breakpoints tend to preserve in-frame translation and globularity, and 5&#x02032; and 3&#x02032; fusion partners generally contribute to different structural elements to fusion proteins.</p></sec><sec id="SEC2-3"><title>Expression and regulation of fusion proteins</title><p>The principles that govern the expression and regulation of fusion proteins are currently insufficiently understood, but several pilot studies have begun to sketch an initial portrait of fusion protein regulation. A screen of 7424 putative fusion transcripts used RNA sequencing and mass spectrometry to confirm the expression of 175 fusion transcripts in 16 human tissues (<xref rid="B84" ref-type="bibr">84</xref>). The expression of fusion proteins was generally found to be low, and much more tissue specific than for other proteins (Figure <xref ref-type="fig" rid="F4">4A</xref>). A survey of transcription read-through fusions in prostate cancer found a correlation between parent gene expression and fusion transcript abundance: 5&#x02032; and 3&#x02032; genes with higher expression were more likely to produce observable fusion transcripts. Furthermore, the expression and tissue specificity of the fusion transcript correlated with expression patterns of the upstream parent gene (<xref rid="B1" ref-type="bibr">1</xref>). In accord, a more recent study of transcription read-through fusions in prostate cancer demonstrated that fusion transcript expression is similar to parental expression, and that fusion transcript levels respond similarly to androgen and anti-androgen treatment (<xref rid="B114" ref-type="bibr">114</xref>). By contrast, a study of <italic>cis</italic>-spliced fusions in prostate cancer found that only half of the fusions were significantly expressed relative to the parent genes (<xref rid="B8" ref-type="bibr">8</xref>). These results suggest that different mechanisms of fusion formation may influence the expression levels of the fusion transcripts and proteins.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Expression and regulation of fusion proteins. (<bold>A</bold>) Although the parent proteins that constitute fusion proteins tend to be more highly expressed than average, the expression of fusion proteins tends to be low. Fusion protein expression is highly tissue specific and tends to follow the tissue distribution of the parent proteins. (<bold>B</bold>) 5&#x02032; translocation partners tend to have highly active promoters and 3&#x02032; partners have especially stable UTR regions, which suggests an optimization for increasing fusion transcript and protein levels. (<bold>C</bold>) An increasing number of reports demonstrate that cancer-associated fusions can also be present in healthy, non-diseased tissue. (<bold>D</bold>) The translation of fusion transcripts into fusion proteins is relatively rarely confirmed, which may be partially due to false positive hits from fusion transcript detection algorithms.</p></caption><graphic xlink:href="gkw282fig4"/></fig><p>Similarly, a computational review of translocated genes in hematological cancers confirmed that fusion proteins tend to be lowly expressed and tissue specific, but also reported that the constituent parents of fusion proteins are more highly expressed than average (<xref rid="B47" ref-type="bibr">47</xref>). In particular, 5&#x02032; translocation partners tended to have increased promoter activity and 3&#x02032; partners tended to have increased 3&#x02032; UTR stability. In general, one of the fusion parents (typically the 5&#x02032; gene) was found to predominantly contribute to the overexpression of the fusion protein instead of contributing structural features such as domains. Hence, 5&#x02032; partners appear to supply expression gains while 3&#x02032; supply functional protein segments and stability, which together could increase the expression of fusion proteins (Figure <xref ref-type="fig" rid="F4">4B</xref>). Given these trends, it remains unclear why, in practice, fusion transcript and protein expression levels are so low (<xref rid="B115" ref-type="bibr">115</xref>) (Figure <xref ref-type="fig" rid="F4">4C</xref>). A complicating aspect is the well-documented fact that false positive hits are a common occurrence in fusion transcript detection (<xref rid="B116" ref-type="bibr">116</xref>,<xref rid="B117" ref-type="bibr">117</xref>), which could artificially lower estimates of fusion protein expression by inflating the number of putative fusion transcripts.</p><p>Importantly, the expression of fusion proteins is not restricted to cancer tissue&#x02014;the presence of fusion transcripts or proteins in normal cells has been known for years (<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B84" ref-type="bibr">84</xref>,<xref rid="B118" ref-type="bibr">118</xref>&#x02013;<xref rid="B121" ref-type="bibr">121</xref>) (Figure <xref ref-type="fig" rid="F4">4D</xref>). For example, in the recent fusion screen of TCGA, 192 gene fusions were identified from 364 normal tissue samples (<xref rid="B10" ref-type="bibr">10</xref>). The function of fusions in healthy tissues is unclear, but has been suggested to increase the complexity of the proteome (<xref rid="B115" ref-type="bibr">115</xref>,<xref rid="B119" ref-type="bibr">119</xref>,<xref rid="B122" ref-type="bibr">122</xref>). After finding that translocation-induced fusion proteins seen in cancers were very rarely expressed in normal tissues, one study has suggested that there may be two, mostly non-overlapping sets of gene fusions&#x02014;those associated with cancer and those found in normal tissue (<xref rid="B84" ref-type="bibr">84</xref>). However, the story behind the expression of fusion transcripts is likely much more complex&#x02014;for instance, the recurrent <italic>VTI1A-TCF7L2</italic> fusion has been found in 42% samples of colorectal cancer samples, but also in 29% of normal colonic mucosa samples and, remarkably, in 25% of tested normal tissues from other organs (<xref rid="B123" ref-type="bibr">123</xref>). Further, the overactive production of certain apparently &#x02018;normal&#x02019; fusions has been associated with cancer: for example, the constitutive expression of the <italic>JAZF1-JJAZ1</italic> fusion protein is pro-neoplastic in endometrial stromal sarcoma, but the same fusion protein is also found in benign tissues at lower levels (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B124" ref-type="bibr">124</xref>). Similarly, the <italic>SLC45A3-ELK4</italic> fusion transcript is detected in both prostate cancer and benign prostate tissue, but is expressed at a higher level in the cancerous state (<xref rid="B125" ref-type="bibr">125</xref>). Further studies&#x02014;especially global analyses that can capture the dominant trends of fusion protein expression across many (diseased and normal) human tissues&#x02014;are urgently called for.</p></sec></sec><sec id="SEC3"><title>DETECTING, PRIORITIZING AND ORGANIZING ONCOGENIC GENE FUSIONS</title><p>Historically, gene fusions have been associated with hematological cancers, partially because the complexity of the genomic changes in solid tumors confounded the available molecular cytogenetic methods (<xref rid="B126" ref-type="bibr">126</xref>). The advent of next-generation sequencing (NGS) technology, especially paired-end transcriptome sequencing (PE RNA-seq), and the development of complementary bioinformatics algorithms have revolutionized the detection of gene fusions and underscored the importance of fusions in solid tumors (<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B127" ref-type="bibr">127</xref>&#x02013;<xref rid="B129" ref-type="bibr">129</xref>). These improved methods have discovered numerous novel gene fusions critical for cancer development (<xref rid="B130" ref-type="bibr">130</xref>). For example, bioinformatics approaches led to the discovery of the <italic>TMPRSS2-ETS</italic> gene fusion in prostate cancer (<xref rid="B129" ref-type="bibr">129</xref>) and the <italic>EML4-ALK</italic> fusion in non-small-cell lung cancer (<xref rid="B66" ref-type="bibr">66</xref>). The clinical importance of detecting <italic>bona fide</italic> gene fusions in tumor cells translates into a need for highly accurate and sensitive fusion detection and prioritization, while the rise in the number of gene fusion studies necessitates specialized databases and web services. Although gene fusion algorithms have been well-reviewed, prioritization algorithms and databasing work requires further dissemination.</p><sec id="SEC3-1"><title>Detecting gene fusions in cancer</title><p>In recent years, there has been a remarkably concerted effort to develop algorithms and tools for identifying gene fusions from sequencing data. The first dedicated software, FusionSeq, was published in 2010 (<xref rid="B131" ref-type="bibr">131</xref>); by the end of 2012, 15 other tools had been released. At present, we find 30 different methods for identifying gene fusions (<xref rid="B131" ref-type="bibr">131</xref>&#x02013;<xref rid="B158" ref-type="bibr">158</xref>) (Table <xref ref-type="table" rid="tbl1">1</xref>), with the contenders for the most widely used packages being TopHat-Fusion (<xref rid="B157" ref-type="bibr">157</xref>) and deFuse (<xref rid="B152" ref-type="bibr">152</xref>). In addition, many other software packages, such as BreakDancer (<xref rid="B159" ref-type="bibr">159</xref>) and CREST (<xref rid="B160" ref-type="bibr">160</xref>), can call gene fusions in addition to other structural rearrangements. In the last 2 years, several additional fusion mapping tools have been released&#x02014;FusionMetaCaller (<xref rid="B161" ref-type="bibr">161</xref>), JAFFA (<xref rid="B133" ref-type="bibr">133</xref>), IDP-fusion (<xref rid="B132" ref-type="bibr">132</xref>), TRUP (<xref rid="B134" ref-type="bibr">134</xref>), FusionCatcher and PRADA (<xref rid="B136" ref-type="bibr">136</xref>). A number of supporting tools, such as the Bioconductor package Chimera (<xref rid="B162" ref-type="bibr">162</xref>), offer utilities for organizing, analyzing and validating gene fusion lists reported by detection tools.</p><table-wrap id="tbl1" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Software packages, algorithms and tools for identifying gene fusions from sequencing data</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="left" rowspan="1" colspan="1">Notable features</th><th align="left" rowspan="1" colspan="1">URL</th><th align="left" rowspan="1" colspan="1">PMID</th><th align="left" rowspan="1" colspan="1">Year</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>FusionMetaCaller</bold></td><td align="left" rowspan="1" colspan="1">An ensemble of the three fusion transcript detection algorithms (SOAPfuse, FusionCatcher and JAFFA) with the best performance on three synthetic and three real PE RNA-seq cancer data sets. R package.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://tsenglab.biostat.pitt.edu/software.htm">http://tsenglab.biostat.pitt.edu/software.htm</ext-link></td><td align="left" rowspan="1" colspan="1">26582927</td><td align="left" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>INTEGRATE</bold></td><td align="left" rowspan="1" colspan="1">Combines WGS for structural variant detection with RNA-seq to detect expressed gene fusion transcripts. Emphasizes the minimization of false positive hit rate.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/integrate-fusion/">https://sourceforge.net/projects/integrate-fusion/</ext-link></td><td align="left" rowspan="1" colspan="1">26556708</td><td align="left" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>IDP-fusion</bold></td><td align="left" rowspan="1" colspan="1">Detects gene fusions, identifies junctions and quantifies fusion isoforms by integrating third-generation sequencing long reads and second-generation sequencing short reads.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.healthcare.uiowa.edu/labs/au/IDP-fusion/">http://www.healthcare.uiowa.edu/labs/au/IDP-fusion/</ext-link></td><td align="left" rowspan="1" colspan="1">26040699</td><td align="left" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>JAFFA</bold></td><td align="left" rowspan="1" colspan="1">Fusion transcript detection algorithm optimized for reads of 100 base pairs or greater. Uses a known transcriptome as an alignment reference instead of genome.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://github.com/Oshlack/JAFFA/wiki">https://github.com/Oshlack/JAFFA/wiki</ext-link></td><td align="left" rowspan="1" colspan="1">26019724</td><td align="left" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TRUP</bold></td><td align="left" rowspan="1" colspan="1">Detects fusion transcripts from PE RNA-seq data. Performs split read mapping and assembly of potential breakpoint regions. Filters include thresholds on repeat content and number of supporting reads.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://github.com/ruping/TRUP">https://github.com/ruping/TRUP</ext-link></td><td align="left" rowspan="1" colspan="1">25650807</td><td align="left" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ChildDecode</bold></td><td align="left" rowspan="1" colspan="1">Detects several predefined pathognomonic gene fusions in childhood sarcomas from RNA-seq data. Operates on cloud-computing platform. Part of the FUSIONCloud commercial analytical platform.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.fusiongenomics.com/onetest-products/">http://www.fusiongenomics.com/onetest-products/</ext-link></td><td align="left" rowspan="1" colspan="1">24517889</td><td align="left" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionCatcher</bold></td><td align="left" rowspan="1" colspan="1">Detects somatic fusion transcripts. Uses ensemble approach of four different methods and aligners to identify fusion junctions. Discordantly mapping reads are filtered on gene identity and positioning.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://github.com/ndaniel/fusioncatcher">https://github.com/ndaniel/fusioncatcher</ext-link></td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/011650">http://dx.doi.org/10.1101/011650</ext-link></td><td align="left" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PRADA</bold></td><td align="left" rowspan="1" colspan="1">Uses dual-mapping strategy of aligning paired-end reads to a combined genome and transciptome reference to detect fusion transcripts. Outputs fusion frame classification, homology scores and other summary features.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://sourceforge.net/projects/prada/">http://sourceforge.net/projects/prada/</ext-link></td><td align="left" rowspan="1" colspan="1">24695405</td><td align="left" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>EBARDenovo</bold></td><td align="left" rowspan="1" colspan="1">Method for <italic>de novo</italic> assembly of short RNA-seq reads with a focus on detecting fusion transcripts. Optimized to handle confounding assembly errors. sequencing errors, repetitive sequences and amplicons.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://ebardenovo.sourceforge.net/">http://ebardenovo.sourceforge.net/</ext-link></td><td align="left" rowspan="1" colspan="1">23457040</td><td align="left" rowspan="1" colspan="1">2013</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionQ</bold></td><td align="left" rowspan="1" colspan="1">Detects gene fusions from PE RNA-seq data, reconstructs features of fusion transcripts and estimates their abundances. Uses a residual sequence extension method to extend short reads.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://sites.google.com/site/fusionq1/home/">https://sites.google.com/site/fusionq1/home/</ext-link></td><td align="left" rowspan="1" colspan="1">23768108</td><td align="left" rowspan="1" colspan="1">2013</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>iFUSE</bold></td><td align="left" rowspan="1" colspan="1">Web-based visualization tool for structural variants that prioritizes breaks that are likely to be associated with gene fusions. Provides candidate transcript and protein sequences resulting from the identified gene fusions.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://ifuse.erasmusmc.nl">http://ifuse.erasmusmc.nl</ext-link></td><td align="left" rowspan="1" colspan="1">23661695</td><td align="left" rowspan="1" colspan="1">2013</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SOAPFuse</bold></td><td align="left" rowspan="1" colspan="1">Identifies fusion transcripts through discordant PE reads and junction spanning reads. Features an improved algorithm for constructing the putative junction library and a relatively high computational efficiency.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://soap.genomics.org.cn/soapfuse.html">http://soap.genomics.org.cn/soapfuse.html</ext-link></td><td align="left" rowspan="1" colspan="1">23409703</td><td align="left" rowspan="1" colspan="1">2013</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SOAPfusion</bold></td><td align="left" rowspan="1" colspan="1">Part of the SOAP software for genome-wide detection of gene fusions from PE RNA-Seq data. Focuses on high sensitivity and low false discovery rates at low coverage.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://soap.genomics.org.cn/SOAPfusion.html">http://soap.genomics.org.cn/SOAPfusion.html</ext-link></td><td align="left" rowspan="1" colspan="1">24123671</td><td align="left" rowspan="1" colspan="1">2013</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Bellerophontes</bold></td><td align="left" rowspan="1" colspan="1">Identifies fusion transcripts from PE data. Selects from fusion candidates using a 'gene fusion model', and features splice site and abundance analyses that provide a more accurate set of junction reads.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://eda.polito.it/bellerophontes/">http://eda.polito.it/bellerophontes/</ext-link></td><td align="left" rowspan="1" colspan="1">22711792</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BreakFusion</bold></td><td align="left" rowspan="1" colspan="1">Detects fusion transcripts using a targeted transcriptome assembly strategy. Introduces a single statistical chimeric score that summarizes the likelihood of a junction sequence containing true breakpoints.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://bioinformatics.mdanderson.org/main/BreakFusion">http://bioinformatics.mdanderson.org/main/BreakFusion</ext-link></td><td align="left" rowspan="1" colspan="1">22563071</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>elDorado</bold></td><td align="left" rowspan="1" colspan="1">Commercial software for identifying fusions from paired-end RNA seq reads. Filters on fusion structure and read support. Introduces the Transcriptome Viewer, a tool for visualizing gene fusions.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.genomatix.de/online_help/help_eldorado/introduction.html">https://www.genomatix.de/online_help/help_eldorado/introduction.html</ext-link></td><td align="left" rowspan="1" colspan="1">23036331</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>EricScript</bold></td><td align="left" rowspan="1" colspan="1">Detects fusion transcripts from PE data. Can create synthetic gene fusions with the EricScript simulator, and EricScript CalcStats can generate summary statistics for scoring fusion detection methods.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://sites.google.com/site/bioericscript/">https://sites.google.com/site/bioericscript/</ext-link></td><td align="left" rowspan="1" colspan="1">23093608</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionAnalyser</bold></td><td align="left" rowspan="1" colspan="1">A graphical tool for detecting fusion transcripts from PE data that provides a user-friendly GUI and filtering system for non-programmers.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ilte-cml.org/FusionAnalyser/">http://www.ilte-cml.org/FusionAnalyser/</ext-link></td><td align="left" rowspan="1" colspan="1">22570408</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionFinder</bold></td><td align="left" rowspan="1" colspan="1">Identifies gene fusion partners from either SE or PE RNA-seq data. Filters on features including read-through transcripts, homology and antisense information.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://bioinformatics.childhealthresearch.org.au/software/fusionfinder/">http://bioinformatics.childhealthresearch.org.au/software/fusionfinder/</ext-link></td><td align="left" rowspan="1" colspan="1">22761941</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>LifeScope</bold></td><td align="left" rowspan="1" colspan="1">GUI-based splice and fusion detection from RNA-seq data method. Available from within the LifeScope software package.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/uk/en/home/technical-resources/software-downloads/lifescope-genomic-analysis-software.html">https://www.thermofisher.com/uk/en/home/technical-resources/software-downloads/lifescope-genomic-analysis-software.html</ext-link></td><td align="left" rowspan="1" colspan="1">22496636</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>nFuse</bold></td><td align="left" rowspan="1" colspan="1">Detects fusion transcripts and related chromosomal rearrangements from matched RNA-seq and whole genome shotgun sequencing data.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://code.google.com/p/nfuse/">https://code.google.com/p/nfuse/</ext-link></td><td align="left" rowspan="1" colspan="1">22745232</td><td align="left" rowspan="1" colspan="1">2012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ChimeraScan</bold></td><td align="left" rowspan="1" colspan="1">Detects fusion transcripts from PE RNA-seq data. Automatically generates HTML reports to facilitate results analysis.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://code.google.com/p/chimerascan/">http://code.google.com/p/chimerascan/</ext-link></td><td align="left" rowspan="1" colspan="1">21840877</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Comrad</bold></td><td align="left" rowspan="1" colspan="1">Performs an integrated analysis of RNA-Seq and WGS data to detect genomic rearrangements and fusion transcripts. Handles low coverage genome data.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://code.google.com/p/comrad/">http://code.google.com/p/comrad/</ext-link></td><td align="left" rowspan="1" colspan="1">21478487</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>deFuse</bold></td><td align="left" rowspan="1" colspan="1">Uses discordant paired end alignments to guide the split read analysis. Does not discard ambiguously mapping reads, but considers all possible alignments and fusion boundaries and resolve the most probable position.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://sourceforge.net/apps/mediawiki/defuse/">http://sourceforge.net/apps/mediawiki/defuse/</ext-link></td><td align="left" rowspan="1" colspan="1">21625565</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionHunter</bold></td><td align="left" rowspan="1" colspan="1">Detects fusion transcripts from PE data. Can identify transcript fragments without known annotations. Filters on anchor length, read-through transcripts, junction reads and PCR artifacts.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://bioen-compbio.bioen.illinois.edu/FusionHunter/">http://bioen-compbio.bioen.illinois.edu/FusionHunter/</ext-link></td><td align="left" rowspan="1" colspan="1">21546395</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionMap</bold></td><td align="left" rowspan="1" colspan="1">Fusion gene detection from either SE or PE RNA-seq or gDNA-seq data. Focuses on improving the accuracy of mapping junction-spanning single reads.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.omicsoft.com/fusionmap/">http://www.omicsoft.com/fusionmap/</ext-link></td><td align="left" rowspan="1" colspan="1">21593131</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ShortFuse</bold></td><td align="left" rowspan="1" colspan="1">Fusion transcript detection from PE RNA-seq data. Focuses on accurately identifying fusion transcripts when many read pairs map ambiguously.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://bitbucket.org/mckinsel/shortfuse">https://bitbucket.org/mckinsel/shortfuse</ext-link></td><td align="left" rowspan="1" colspan="1">21330288</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SnowShoes-FTD</bold></td><td align="left" rowspan="1" colspan="1">Fusion transcript detection from PE RNA-seq data. Includes prediction of genomic rearrangements, fusion protein sequence reconstruction and generation of fusion spanning sequence for PCR validation.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://mayoresearch.mayo.edu/mayo/research/biostat/%20stand-alone-packages.cfm">http://mayoresearch.mayo.edu/mayo/research/biostat/ stand-alone-packages.cfm</ext-link></td><td align="left" rowspan="1" colspan="1">21622959</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TopHat-Fusion</bold></td><td align="left" rowspan="1" colspan="1">A version of TopHat specialized for the detection of fusion transcripts. Implements a two stage process of aligning reads to genomic reference using altered version of TopHat, then a processing step to incorporate annotation and filter candidates.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://tophat-fusion.sourceforge.net/">http://tophat-fusion.sourceforge.net/</ext-link></td><td align="left" rowspan="1" colspan="1">21835007</td><td align="left" rowspan="1" colspan="1">2011</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionSeq</bold></td><td align="left" rowspan="1" colspan="1">Fusion transcript detection from PE RNA-seq data. Considers annotated exons during mapping procedure, and reports read-through fusions in addition to other fusions. Variety of filters, including comparing fusion expression with general expression.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://archive.gersteinlab.org/proj/rnaseq/fusionseq/">http://archive.gersteinlab.org/proj/rnaseq/fusionseq/</ext-link></td><td align="left" rowspan="1" colspan="1">20964841</td><td align="left" rowspan="1" colspan="1">2010</td></tr></tbody></table><table-wrap-foot><fn id="TFN001"><p>GUI = graphical user interface, PCR = polymerase chain reaction, PE = paired-end, RNA-seq = RNA sequencing, SE = single end, WGS = whole genome sequencing.</p></fn></table-wrap-foot></table-wrap><p>The mechanisms, performance and features of different gene fusion detection algorithms have been well reviewed (<xref rid="B130" ref-type="bibr">130</xref>,<xref rid="B163" ref-type="bibr">163</xref>&#x02013;<xref rid="B166" ref-type="bibr">166</xref>). Practical concerns&#x02014;like the memory usage and computing time of detection algorithms&#x02014;limit some tools (<xref rid="B134" ref-type="bibr">134</xref>), but this constraint is likely to decrease in importance as computing power continues to expand. Most recently, the performance and computational cost of 15 popular fusion detection algorithms was evaluated under a variety of experimental conditions, and a meta-caller algorithm that blended the three top performing methods to produce improved predictions was released as an R package (<xref rid="B161" ref-type="bibr">161</xref>). Meta-algorithms, or ensembles of different algorithms, often improve classification performance (<xref rid="B167" ref-type="bibr">167</xref>) and are likely to become more popular in fusion detection, especially since different fusion detection algorithms can be plagued by little predictive overlap (<xref rid="B142" ref-type="bibr">142</xref>,<xref rid="B168" ref-type="bibr">168</xref>). The difficulties of calling genuine gene fusions&#x02014;including the complexity and instability of many cancer genomes, and technical errors in the sequencing or alignment procedure&#x02014;are also well covered (<xref rid="B116" ref-type="bibr">116</xref>,<xref rid="B117" ref-type="bibr">117</xref>,<xref rid="B130" ref-type="bibr">130</xref>,<xref rid="B169" ref-type="bibr">169</xref>). In the rest of this section, we focus on methods for deciding which fusions are likely to be drivers and on gene fusion databases.</p></sec><sec id="SEC3-2"><title>Identifying driver gene fusions</title><p>Given the unprecedented sensitivity of gene fusion detection, and the repeated identification of fusion transcripts in normal cells, it is increasingly important to separate driver fusions from passenger mutations. Although many fusion detection tools encode their own filters in order to cut down on false positive calls (<xref rid="B166" ref-type="bibr">166</xref>), the criteria are most often based on read mapping quality and the presence of certain sequence features. Biological approaches that rank fusion candidates by some notion of functional importance are complementary and can offer a significant improvement in removing false positive calls.</p><p>The first integrative bioinformatics study with the goal of distinguishing &#x02018;driver&#x02019; from &#x02018;passenger&#x02019; fusions in high-throughput data took a gene-centric approach, ranking each gene by its similarity to &#x02018;molecular concepts&#x02019; characteristic of cancer genes (<xref rid="B49" ref-type="bibr">49</xref>). These characteristics included specific functional annotations, pathway involvements protein interactions and domains. Interestingly, domain architectures and shared pathways were not nearly as indicative of cancer-related fusion genes as specific gene ontologies and the engagement of distinct interaction networks (e.g. fusion genes in acute lymphoblastic lymphoma tend to frequently interact with <italic>GATA3</italic>) (<xref rid="B49" ref-type="bibr">49</xref>). Notably, while point mutated cancer genes tended to be involved in DNA repair and cell cycle checkpoints, driver fusions tended to include genes with signal transduction and transcription activation functions. Further, by analyzing high-throughput copy number genomic data, recurrent gene fusion events were found to be associated with consistent, specific patterns of copy number alteration. These trends were used to design an algorithm for ranking genes by their ability to form driver fusions.</p><p>Prioritization of gene fusions using characteristics from only one gene is necessarily incomplete, because gene fusions generally involve two partner genes. Wu <italic>et&#x000a0;al</italic>. addressed this concern using the concept of network centrality (<xref rid="B170" ref-type="bibr">170</xref>). They observed that in most known cancer fusion gene pairs, at least one of the fusion partners acts as a hub (i.e. has many interaction partners) in a gene interaction network (where genes are nodes and edges indicate a regulatory or protein&#x02013;protein interaction). Many fusions were found to be formed from two hubs, possibly because the central positioning of hub-like genes confers a large radius of influence, maximizing the deregulation of other genes and pathways if they are fused or disrupted. A network centrality based classifier was developed for scoring fusions, which showed superior performance compared to both the above method (<xref rid="B49" ref-type="bibr">49</xref>) and a simpler gene-based model that selects drivers based on whether the fusion includes a cancer-associated gene.</p><p>Oncofuse (<xref rid="B95" ref-type="bibr">95</xref>) innovated the use of fusion sequences, instead of gene qualities, to identify driver fusions. First, a set of 24 features of fusion transcripts was built up, including functional profiles, tissue-specific expression, replication timing of the gene-containing locus, interaction partners, interaction partner expression, 3&#x02032; UTR length and domains. Notably, both retained and lost features were included in the dataset, e.g. the domains that were both lost and retained as a result of the fusion breakpoint position. A Na&#x000ef;ve Bayes classifier was trained on these feature sets, which contained both positive data (known oncogenic fusions) and negative data (fusion genes and read-through transcripts found in normal cells). Functional profile information provided the largest information gain for classification&#x02014;molecular functions related to transcription factors, kinases and histone modification were highly enriched in driver fusions. This echoes previous results (<xref rid="B49" ref-type="bibr">49</xref>). Expression and replication features were most important for 5&#x02032; partners, which also resonates with other literature (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B47" ref-type="bibr">47</xref>). Interestingly, certain lost features, like protein interaction interfaces, were more informative than the retained features.</p><p>The most recent method for nominating fusion drivers is the Pegasus pipeline (<xref rid="B86" ref-type="bibr">86</xref>), which emphasizes transcript sequence reconstruction and domain annotation. Pegasus extends the Oncofuse domain analysis by considering reading frame conservation and all possible isoforms. Specifically, Pegasus reconstructs the fusion transcript sequence for each gene fusion candidate, annotates breakpoints as occurring in the CDS, introns or UTRs, and assesses reading frames. Lost and retained domains of the 5&#x02032; and 3&#x02032; partners are determined, and certain domain features (e.g. oncogenic domains) are annotated. A gradient tree boosting algorithm is trained on positive driver fusions from ChimerDB 2.0 (<xref rid="B171" ref-type="bibr">171</xref>) and on a complex negative dataset (composed of passenger fusions, read-through transcripts in normal tissue, etc.). In-frame transcripts were found to by far be the most distinguishing feature of driver fusions. Other important factors included breakpoints in the CDS and domains from known oncogenes (or domains interacting with known oncogenes). Pegasus performed well on the curated validation set and on real RNA-seq data, and outperformed Oncofuse in several tests. It is probable that the identification of driver fusions, either with these existing tools or with new methods, will play an increasingly important role in cancer research as the number and size of fusion-detecting studies continues to expand.</p></sec><sec id="SEC3-3"><title>Curating knowledge on oncogenic gene fusions</title><p>The rapid increase of gene fusion data requires significant organizational effort, and at present almost a dozen databases of oncogenic fusion genes exist (Table <xref ref-type="table" rid="tbl2">2</xref>). Some of the earliest efforts to catalog gene fusions, such as the Atlas of Genetics and Cytogenetics in Oncology and Haematology (<xref rid="B172" ref-type="bibr">172</xref>), arose before the advent of deep sequencing of the transcriptome. Most currently available databases leverage sequence technology advances but vary significantly in their methodology, focuses and sizes&#x02014;for example, the &#x0223c;29 000 fusion transcripts in ChiTaRS result mainly from bioinformatics analyses of public databases, while the &#x0223c;2600 chromosome rearrangements in dbCRID are manually curated from the literature. Here, we outline the progress made by recent gene fusion databases. We only focus on databases that concentrate on gene fusions, but related resources such as the database of genomic variants (<xref rid="B173" ref-type="bibr">173</xref>) or the DECIPHER database of chromosome imbalances and phenotypes (<xref rid="B174" ref-type="bibr">174</xref>) also include gene fusions.</p><table-wrap id="tbl2" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Databases of gene fusions</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Database name</th><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Data sources</th><th align="left" rowspan="1" colspan="1">URL</th><th align="left" rowspan="1" colspan="1">PMID</th><th align="left" rowspan="1" colspan="1">Database size (in current release or as of October 2015)</th><th align="left" rowspan="1" colspan="1">First published and current database release</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Mitelman</bold></td><td align="left" rowspan="1" colspan="1">Relates gene fusions and other chromosomal aberrations to tumor characteristics, based either on individual cases or associations.</td><td align="left" rowspan="1" colspan="1">Manual literature curation.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://cgap.nci.nih.gov/Chromosomes/Mitelman">http://cgap.nci.nih.gov/Chromosomes/Mitelman</ext-link></td><td align="left" rowspan="1" colspan="1">17361217 (review)</td><td align="left" rowspan="1" colspan="1">10 026 gene fusions; 65 975 patient cases</td><td align="left" rowspan="1" colspan="1">1994&#x02013;2015. Current release: August 2014</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>COSMIC Curated Fusions</bold></td><td align="left" rowspan="1" colspan="1">Catalog of translocations and fusions between gene pairs supplemented with extensive clinical data.</td><td align="left" rowspan="1" colspan="1">Manual literature curation.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cosmic/help/fusion/overview">http://cancer.sanger.ac.uk/cosmic/help/fusion/overview</ext-link></td><td align="left" rowspan="1" colspan="1">25355519 (full 2015 COSMIC db)</td><td align="left" rowspan="1" colspan="1">10 534 gene fusions</td><td align="left" rowspan="1" colspan="1">2004&#x02013;2015. Current release: v70 (2014)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FARE-CAF&#x000c9;</bold></td><td align="left" rowspan="1" colspan="1">Database of functional and regulatory elements in gene fusion events related to cancer.</td><td align="left" rowspan="1" colspan="1">Integration of diverse data sets, including fusion events, molecular and regulatory features.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://ppi.bioinfo.asia.edu.tw/FARE-CAFE">http://ppi.bioinfo.asia.edu.tw/FARE-CAFE</ext-link>.</td><td align="left" rowspan="1" colspan="1">26384373</td><td align="left" rowspan="1" colspan="1">1587 gene fusions</td><td align="left" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TCGA Fusion Gene Data Portal</bold></td><td align="left" rowspan="1" colspan="1">Repository for the results of the landscape of cancer-associated fusion study carried out using the PRADA pipeline.</td><td align="left" rowspan="1" colspan="1">Integrated analysis of paired-end RNA sequencing and DNA copy number data from TCGA.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://54.84.12.177/PanCanFusV2/">http://54.84.12.177/PanCanFusV2/</ext-link></td><td align="left" rowspan="1" colspan="1">25500544</td><td align="left" rowspan="1" colspan="1">7887 fusion transcripts</td><td align="left" rowspan="1" colspan="1">2015. Current release: December, 2014.</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FusionCancer</bold></td><td align="left" rowspan="1" colspan="1">Fusion gene database derived exclusively from cancer RNA-seq data.</td><td align="left" rowspan="1" colspan="1">Compiled from 591 recently published RNA-seq datasets covering 15 kinds of human cancer.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://donglab.ecnu.edu.cn/databases/FusionCancer/">http://donglab.ecnu.edu.cn/databases/FusionCancer/</ext-link></td><td align="left" rowspan="1" colspan="1">26215638</td><td align="left" rowspan="1" colspan="1">11 839 gene fusions</td><td align="left" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ChiTaRS</bold></td><td align="left" rowspan="1" colspan="1">Catalogue of fusion transcripts in humans, mice, fruit flies, zebrafishes, cows, rats, pig and yeast.</td><td align="left" rowspan="1" colspan="1">Bioinformatic analysis of ESTs and mRNAS from GenBank.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://chitars.bioinfo.cnio.es/">http://chitars.bioinfo.cnio.es/</ext-link></td><td align="left" rowspan="1" colspan="1">25414346 (2.1); 23143107</td><td align="left" rowspan="1" colspan="1">29 159 fusion transcripts</td><td align="left" rowspan="1" colspan="1">2013. Current release: ChiTaRS 2.1 (2014)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>dbCRID</bold></td><td align="left" rowspan="1" colspan="1">Curated database of human chromosomal rearrangements, associated diseases and clinical symptoms.</td><td align="left" rowspan="1" colspan="1">Manual literature curation.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://dbcrid.biolead.org/">http://dbcrid.biolead.org/</ext-link></td><td align="left" rowspan="1" colspan="1">21051346</td><td align="left" rowspan="1" colspan="1">2643 chromosome rearrangements</td><td align="left" rowspan="1" colspan="1">2011. Current release: v 0.9 (2010)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ConjoinG</bold></td><td align="left" rowspan="1" colspan="1">Database of conjoined genes (transcription read-through fusions).</td><td align="left" rowspan="1" colspan="1">Manual literature curation and bioinformatic analysis of EST and mRNA sequences from GenBank.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://metasystems.riken.jp/conjoing/">http://metasystems.riken.jp/conjoing/</ext-link></td><td align="left" rowspan="1" colspan="1">20967262</td><td align="left" rowspan="1" colspan="1">800 conjoined genes from 1542 parent genes</td><td align="left" rowspan="1" colspan="1">2010</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HYBRIDdb</bold></td><td align="left" rowspan="1" colspan="1">Database of hybrid genes in the human genome.</td><td align="left" rowspan="1" colspan="1">Analysis of mRNA, EST, cDNA and genomic DNA sequences in the INSDC resource.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.primate.or.kr/hybriddb/">http://www.primate.or.kr/hybriddb/</ext-link></td><td align="left" rowspan="1" colspan="1">17519042</td><td align="left" rowspan="1" colspan="1">3404 gene fusions</td><td align="left" rowspan="1" colspan="1">2007</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TICdb</bold></td><td align="left" rowspan="1" colspan="1">Finely mapped translocation breakpoints in cancer.</td><td align="left" rowspan="1" colspan="1">Manual literature curation and analysis of public databases (Mitelman, GenBank).</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.unav.es/genetica/TICdb/">http://www.unav.es/genetica/TICdb/</ext-link></td><td align="left" rowspan="1" colspan="1">17257420</td><td align="left" rowspan="1" colspan="1">1374 fusion sequences from 431 different genes</td><td align="left" rowspan="1" colspan="1">2007. Current release: release 3.3 (2013)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ChimerDB</bold></td><td align="left" rowspan="1" colspan="1">Knowledgebase of fusion transcripts across multiple species, as well as information on cancer breakpoints.</td><td align="left" rowspan="1" colspan="1">Bioinformatics analysis of Sanger CGP, OMIM, PubMed and the Mitelman's database and transcript sequences in GenBank.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://biome.ewha.ac.kr:8080/FusionGene/">http://biome.ewha.ac.kr:8080/FusionGene/</ext-link></td><td align="left" rowspan="1" colspan="1">19906715 (2.0); 16381848</td><td align="left" rowspan="1" colspan="1">2699 fusion transcripts</td><td align="left" rowspan="1" colspan="1">2006. Current release: ChimerDB 2.0 (2010)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>DACRO</bold></td><td align="left" rowspan="1" colspan="1">Database of all published chromosomal rearrangements that are associated with an abnormal phenotype.</td><td align="left" rowspan="1" colspan="1">Online searches of PubMed, Scopus and OMIM.</td><td align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="https://www1.hgu.mrc.ac.uk/Softdata/Translocation/">https://www1.hgu.mrc.ac.uk/Softdata/Translocation/</ext-link></td><td align="left" rowspan="1" colspan="1">Unpublished</td><td align="left" rowspan="1" colspan="1">965 translocations</td><td align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="TFN002"><p>Databases are annotated with source data types, URLs, estimates of database content and size and first and current releases. EST = expressed sequence tag, INSDC = International Nucleotide Sequence Database Collaboration, OMIM = Online Mendelian Inheritance in Man, Sanger CGP = Sanger Cancer Genome Project, TCGA = The Cancer Genome Atlas.</p></fn></table-wrap-foot></table-wrap><p>Initial efforts to catalog gene fusions included (early versions of) the Mitelman database, COSMIC (<xref rid="B175" ref-type="bibr">175</xref>), ChimerDB (<xref rid="B171" ref-type="bibr">171</xref>,<xref rid="B176" ref-type="bibr">176</xref>), TICdb (<xref rid="B177" ref-type="bibr">177</xref>) and HYBRIDdb (<xref rid="B178" ref-type="bibr">178</xref>). The Mitelman database of chromosomal aberrations and gene fusions began as early as 1994, appearing in print and on CD-ROM, and has grown into one of the most popular current resources on gene fusions (<xref rid="B179" ref-type="bibr">179</xref>). This heavily curated database of fusions is supplemented with clinical association information, like karyotype abnormalities associated with a particular tumor type or patient prognosis. The database is searchable by a wide variety of fields, such as patient age, publication authors, gene, tumor histology, tissue type, mutation recurrence, associated clinical features and cancer types. Similarly, the COSMIC catalog of somatic mutations in cancer offers an extensive curated collection of oncogenic gene fusions. Initially published in 2004 (<xref rid="B175" ref-type="bibr">175</xref>), the COSMIC database has also grown to significant size and scope (<xref rid="B180" ref-type="bibr">180</xref>). COSMIC's fusion information is manually curated from the literature (though currently only for solid tumors) and incorporates information on inferred breakpoints, included exons of the 5&#x02032; and 3&#x02032; partners, and mutation frequency. Extensive clinical data are also integrated, such as patient details, tumor (stage/drug response) and sample features (histology, source) and tissue-specific fusion mutation frequencies.</p><p>Another relatively early fusion resource, ChimerDB, was initially published in 2006 (<xref rid="B171" ref-type="bibr">171</xref>) and now houses 2700 fusion transcripts (<xref rid="B176" ref-type="bibr">176</xref>), which were identified via bioinformatics analysis of GenBank, the NCBI short read archive, Sanger CGP, OMIM, Mitelman's database and PubMed. The ChimerDB computational pipeline involves aligning fusion sequences to the reference human genome and classifying gene fusions into confidence classes based on the transcript fusion boundary matching exon boundaries. The service offers support for detailed searches (e.g. by gene, chromosomal band and tissue), filtering by alignment (e.g. intact exons at breakpoint) and an alignment viewer. Interestingly, the ChimerDB study reported that the overlap between Sanger CGP, OMIM, Mitelman and their PubMed gene fusion list was relatively small, with almost 60% of fusion pairs found in only one resource, indicating a strong need to integrate fusion datasets. TICdb, a resource of translocation breakpoints in cancer published the year after ChimerDB, is a highly curated database that sought to address the lack of molecular information on gene fusions in the Mitelman database (<xref rid="B177" ref-type="bibr">177</xref>). It was also the first repository to map translocation breakpoints onto the reference genome and provide fusion boundary sequences. TICdb was built by extracting 298 genes involved in reciprocal translocations from the 2006 version of the Mitelman database and searching PubMed and Genbank to find translocation junction sequences. Another early effort by HYBRIDdb (<xref rid="B178" ref-type="bibr">178</xref>) identified 3400 gene fusions from a bioinformatics analysis of mRNA, EST, cDNA and transcript sequences in the NCBI database. Unfortunately no longer functional, the HYBRIDdb resource mapped fusion transcripts and junctions, classified fusions into translocation and transcription-mediated categories and integrated information on splicing sites, domains and associated pathologies and affected tissues.</p><p>The ConjoinG (<xref rid="B181" ref-type="bibr">181</xref>) and dbCRID (<xref rid="B182" ref-type="bibr">182</xref>) databases represented the next wave of fusion databases. The development of the ConjoingG database of &#x02018;conjoined genes&#x02019;, or transcription-induced fusion genes, sought to address the lack of uniformity in annotating conjoined genes in the UCSC, GenBank, Ensembl and Vega databases. ConjoinG computationally identified and curated 800 read-through transcripts that were supported by one or more mRNA or EST sequence in NCBI. Representative conjoined genes were selected and subjected to validation by RT-PCR and sequencing, and the evolutionary conservation and splicing patterns of these fusion events were analyzed. On the other hand, the dbCRID database of chromosomal rearrangements in human diseases focused on documenting chromosomal rearrangements in both tumor and non-tumor diseases, covering several types of chromosomal rearrangements.</p><p>The most recent gene fusion databases include ChiTaRS 2.1 (<xref rid="B183" ref-type="bibr">183</xref>,<xref rid="B184" ref-type="bibr">184</xref>), FusionCancer (<xref rid="B168" ref-type="bibr">168</xref>), the TCGA Fusion Portal (<xref rid="B10" ref-type="bibr">10</xref>) and FARE-CAFE (<xref rid="B88" ref-type="bibr">88</xref>). The ChiTaRS 2.1 database of fusion transcripts and RNA-seq data (<xref rid="B184" ref-type="bibr">184</xref>) is the largest fusion databases and one of the few containing non-human fusion data. It catalogs over 29 000 fusion transcripts, largely from humans, mice and fruit flies. The fusion transcripts were identified via bioinformatics analysis of ESTs and mRNAs from several databases, and some fusion transcripts also have associated expression and tissue specificity data.</p><p>The FusionCancer database is a unique gene fusion repository derived solely from the analysis of raw cancer RNA-seq data (<xref rid="B168" ref-type="bibr">168</xref>). To create FusionCancer, 591 recent RNA-seq datasets from 15 cancer types were compiled and gene fusions identified using several fusion detection packages. Interestingly, though &#x0223c;12 000 gene fusions were identified with at least one software, only 137 fusions were identified by all four. FusionCancer implements information from COSMIC and ChimerDB, and includes breakpoint location, recurrence rate and fusion sequences. A similar methodology underlies the TCGA Fusion Portal&#x02014;using stringent bioinformatic criteria, Yoshihara and coworkers identified over 8600 distinct fusion transcripts from data on 13 different cancer types in the Cancer Genome Atlas (TCGA), many involving genes not previously known to form fusions (<xref rid="B10" ref-type="bibr">10</xref>). These results have illuminated the roles of many gene fusions (see <bold>Section II</bold>) and have been integrated into other resources, such as the Mitelman database. Finally, the most recently released fusion database is FARE-CAFE (<xref rid="B88" ref-type="bibr">88</xref>), a resource of functional and regulatory elements in fusions. This highly integrated database aims to summarize how fusions affect a variety of molecular components and activities, including Pfam domains, domain&#x02013;domain interactions, protein&#x02013;protein interactions and transcription factor functions.</p><p>It is clear that our understanding of the number of gene fusions and their potential functions is far from being complete. Notably, many fusion databases have very limited overlap between the fusions they document. This is certainly partially due to methodological differences in detection and filtering. However, considering the rate at which novel oncogenic fusions are still being discovered (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B57" ref-type="bibr">57</xref>), it is likely that we have still only detected a small fraction of existing fusions, and future research will continue to gradually improve coverage. Furthermore, current databases reflect the fact that we have little knowledge of certain classes of fusion, such as fusions involving genes encoding long non-coding RNAs, despite their documented central role in cancer (<xref rid="B105" ref-type="bibr">105</xref>&#x02013;<xref rid="B107" ref-type="bibr">107</xref>). Finally, although many studies and databases understandably focus on oncogenic fusions, exploring certain poorly understood aspects of fusions which are perhaps not directly related to cancer is likely to synergistically improve our understanding of cancer-related fusions. Such topics include the role of fusions in healthy tissues and non-human organisms, the functions of singleton fusions, and the extent to which &#x02018;known&#x02019; fusions are false positive results. Indeed, our intuition of what constitutes a &#x02018;functional&#x02019; fusion event (e.g. being recurrent, in-frame and only present in diseased tissues) is likely to transform as more information is acquired on these topics. The substantial number of unknown facets of gene fusion functionality presents truly exciting opportunities for future discovery.</p></sec></sec><sec id="SEC4"><title>CONCLUSIONS AND FUTURE DIRECTIONS</title><p>The computational study of fusion genes, transcripts and proteins is still in its infancy. The improved detection and functional characterization of these frequently oncogenic mutations will continue to play an important role in elucidating cancer processes across diverse tumor types. The recent successes in the development of drugs against mutated kinases and chromatin modifying proteins (<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B82" ref-type="bibr">82</xref>,<xref rid="B185" ref-type="bibr">185</xref>,<xref rid="B186" ref-type="bibr">186</xref>), and novel methods of therapeutically downregulating proteins in general (<xref rid="B187" ref-type="bibr">187</xref>,<xref rid="B188" ref-type="bibr">188</xref>), suggest that fusion transcripts and proteins are likely to be promising targets for the next generation of therapeutic agents against cancer, and data-intensive studies of gene fusions have the key role of directing these future avenues of medical research.</p></sec></body><back><sec id="SEC5"><title>FUNDING</title><p>Funding for open access charge: Medical Research Council [MC_U105185859 to M.B. and N.L].</p><p><italic>Conflict of interest statement</italic>. M. M. B. is an Executive Editor of Nucleic Acids Research.</p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nacu</surname><given-names>S.</given-names></name><name><surname>Yuan</surname><given-names>W.</given-names></name><name><surname>Kan</surname><given-names>Z.</given-names></name><name><surname>Bhatt</surname><given-names>D.</given-names></name><name><surname>Rivers</surname><given-names>C.S.</given-names></name><name><surname>Stinson</surname><given-names>J.</given-names></name><name><surname>Peters</surname><given-names>B.A.</given-names></name><name><surname>Modrusan</surname><given-names>Z.</given-names></name><name><surname>Jung</surname><given-names>K.</given-names></name><name><surname>Seshagiri</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples</article-title>
<source>BMC Med. Genomics</source>
<year>2011</year>
<volume>4</volume>
<fpage>11</fpage><pub-id pub-id-type="pmid">21261984</pub-id></element-citation></ref><ref id="B2"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varley</surname><given-names>K.E.</given-names></name><name><surname>Gertz</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>B.S.</given-names></name><name><surname>Davis</surname><given-names>N.S.</given-names></name><name><surname>Bowling</surname><given-names>K.M.</given-names></name><name><surname>Kirby</surname><given-names>M.K.</given-names></name><name><surname>Nesmith</surname><given-names>A.S.</given-names></name><name><surname>Oliver</surname><given-names>P.G.</given-names></name><name><surname>Grizzle</surname><given-names>W.E.</given-names></name><name><surname>Forero</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Recurrent read-through fusion transcripts in breast cancer</article-title>
<source>Breast Cancer Res. Treat.</source>
<year>2014</year>
<volume>146</volume>
<fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">24929677</pub-id></element-citation></ref><ref id="B3"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.-P.</given-names></name><name><surname>Cho</surname><given-names>G.</given-names></name><name><surname>Han</surname><given-names>S.-W.</given-names></name><name><surname>Shin</surname><given-names>J.-Y.</given-names></name><name><surname>Jeong</surname><given-names>E.-G.</given-names></name><name><surname>Song</surname><given-names>S.-H.</given-names></name><name><surname>Lee</surname><given-names>W.-C.</given-names></name><name><surname>Lee</surname><given-names>K.-H.</given-names></name><name><surname>Bang</surname><given-names>D.</given-names></name><name><surname>Seo</surname><given-names>J.-S.</given-names></name><etal/></person-group>
<article-title>Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis</article-title>
<source>Oncogene</source>
<year>2014</year>
<volume>33</volume>
<fpage>5434</fpage><lpage>5441</lpage><pub-id pub-id-type="pmid">24240688</pub-id></element-citation></ref><ref id="B4"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Sklar</surname><given-names>J.</given-names></name></person-group>
<article-title>Gene fusions and RNA trans-splicing in normal and neoplastic human cells</article-title>
<source>Cell Cycle</source>
<year>2009</year>
<volume>8</volume>
<fpage>218</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">19158498</pub-id></element-citation></ref><ref id="B5"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jividen</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group>
<article-title>Chimeric RNAs generated by intergenic splicing in normal and cancer cells</article-title>
<source>Genes, Chromosom. Cancer</source>
<year>2014</year>
<volume>53</volume>
<fpage>963</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">25131334</pub-id></element-citation></ref><ref id="B6"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>M.</given-names></name><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>H.G.</given-names></name><name><surname>Frierson</surname><given-names>H.F.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group>
<article-title>Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation</article-title>
<source>Cancer Discov.</source>
<year>2012</year>
<volume>2</volume>
<fpage>598</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">22719019</pub-id></element-citation></ref><ref id="B7"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Velusamy</surname><given-names>T.</given-names></name><name><surname>Palanisamy</surname><given-names>N.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Sahasrabuddhe</surname><given-names>A.A.</given-names></name><name><surname>Maher</surname><given-names>C.A.</given-names></name><name><surname>Robinson</surname><given-names>D.R.</given-names></name><name><surname>Bahler</surname><given-names>D.W.</given-names></name><name><surname>Cornell</surname><given-names>T.T.</given-names></name><name><surname>Wilson</surname><given-names>T.E.</given-names></name><name><surname>Lim</surname><given-names>M.S.</given-names></name><etal/></person-group>
<article-title>Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia</article-title>
<source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2013</year>
<volume>110</volume>
<fpage>3035</fpage><lpage>3040</lpage><pub-id pub-id-type="pmid">23382248</pub-id></element-citation></ref><ref id="B8"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qin</surname><given-names>F.</given-names></name><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Babiceanu</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Facemire</surname><given-names>L.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Adli</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group>
<article-title>Discovery of CTCF-sensitive cis-spliced fusion RNAs between adjacent genes in human prostate cells</article-title>
<source>PLOS Genet.</source>
<year>2015</year>
<volume>11</volume>
<fpage>e1005001</fpage><pub-id pub-id-type="pmid">25658338</pub-id></element-citation></ref><ref id="B9"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watson</surname><given-names>I.R.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Futreal</surname><given-names>P.A.</given-names></name><name><surname>Chin</surname><given-names>L.</given-names></name></person-group>
<article-title>Emerging patterns of somatic mutations in cancer</article-title>
<source>Nat. Rev. Genet.</source>
<year>2013</year>
<volume>14</volume>
<fpage>703</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">24022702</pub-id></element-citation></ref><ref id="B10"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshihara</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Torres-Garcia</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Vegesna</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.W.</given-names></name></person-group>
<article-title>The landscape and therapeutic relevance of cancer-associated transcript fusions</article-title>
<source>Oncogene</source>
<year>2015</year>
<volume>34</volume>
<fpage>4845</fpage><lpage>4854</lpage><pub-id pub-id-type="pmid">25500544</pub-id></element-citation></ref><ref id="B11"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>F.</given-names></name><name><surname>Johansson</surname><given-names>B.</given-names></name><name><surname>Mertens</surname><given-names>F.</given-names></name></person-group>
<article-title>The impact of translocations and gene fusions on cancer causation</article-title>
<source>Nat. Rev. Cancer</source>
<year>2007</year>
<volume>7</volume>
<fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">17361217</pub-id></element-citation></ref><ref id="B12"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mertens</surname><given-names>F.</given-names></name><name><surname>Johansson</surname><given-names>B.</given-names></name><name><surname>Fioretos</surname><given-names>T.</given-names></name><name><surname>Mitelman</surname><given-names>F.</given-names></name></person-group>
<article-title>The emerging complexity of gene fusions in cancer</article-title>
<source>Nat. Rev. Cancer</source>
<year>2015</year>
<volume>15</volume>
<fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">25998716</pub-id></element-citation></ref><ref id="B13"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lobato</surname><given-names>M.N.</given-names></name><name><surname>Metzler</surname><given-names>M.</given-names></name><name><surname>Drynan</surname><given-names>L.</given-names></name><name><surname>Forster</surname><given-names>A.</given-names></name><name><surname>Pannell</surname><given-names>R.</given-names></name><name><surname>Rabbitts</surname><given-names>T.H.</given-names></name></person-group>
<article-title>Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias</article-title>
<source>J. Natl. Cancer Inst. Monogr.</source>
<year>2008</year>
<volume>39</volume>
<fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18648005</pub-id></element-citation></ref><ref id="B14"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mertens</surname><given-names>F.</given-names></name><name><surname>Antonescu</surname><given-names>C.R.</given-names></name><name><surname>Mitelman</surname><given-names>F.</given-names></name></person-group>
<article-title>Gene fusions in soft tissue tumors: recurrent and overlapping pathogenetic themes</article-title>
<source>Genes, Chromosom. Cancer</source>
<year>2015</year>
<volume>55</volume>
<fpage>291</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">26684580</pub-id></element-citation></ref><ref id="B15"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nam</surname><given-names>R.K.</given-names></name><name><surname>Sugar</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Klotz</surname><given-names>L.H.</given-names></name><name><surname>Yang</surname><given-names>L.-Y.</given-names></name><name><surname>Stanimirovic</surname><given-names>A.</given-names></name><name><surname>Encioiu</surname><given-names>E.</given-names></name><name><surname>Neill</surname><given-names>M.</given-names></name><name><surname>Loblaw</surname><given-names>D.A.</given-names></name><etal/></person-group>
<article-title>Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer</article-title>
<source>Br. J. Cancer</source>
<year>2007</year>
<volume>97</volume>
<fpage>1690</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">17971772</pub-id></element-citation></ref><ref id="B16"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohno</surname><given-names>T.</given-names></name><name><surname>Ichikawa</surname><given-names>H.</given-names></name><name><surname>Totoki</surname><given-names>Y.</given-names></name><name><surname>Yasuda</surname><given-names>K.</given-names></name><name><surname>Hiramoto</surname><given-names>M.</given-names></name><name><surname>Nammo</surname><given-names>T.</given-names></name><name><surname>Sakamoto</surname><given-names>H.</given-names></name><name><surname>Tsuta</surname><given-names>K.</given-names></name><name><surname>Furuta</surname><given-names>K.</given-names></name><name><surname>Shimada</surname><given-names>Y.</given-names></name><etal/></person-group>
<article-title>KIF5B-RET fusions in lung adenocarcinoma</article-title>
<source>Nat. Med.</source>
<year>2012</year>
<volume>18</volume>
<fpage>375</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">22327624</pub-id></element-citation></ref><ref id="B17"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leyten</surname><given-names>G.H.J.M.</given-names></name><name><surname>Hessels</surname><given-names>D.</given-names></name><name><surname>Jannink</surname><given-names>S.A.</given-names></name><name><surname>Smit</surname><given-names>F.P.</given-names></name><name><surname>de&#x000a0;Jong</surname><given-names>H.</given-names></name><name><surname>Cornel</surname><given-names>E.B.</given-names></name><name><surname>de&#x000a0;Reijke</surname><given-names>T.M.</given-names></name><name><surname>Vergunst</surname><given-names>H.</given-names></name><name><surname>Kil</surname><given-names>P.</given-names></name><name><surname>Knipscheer</surname><given-names>B.C.</given-names></name><etal/></person-group>
<article-title>Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer</article-title>
<source>Eur. Urol.</source>
<year>2014</year>
<volume>65</volume>
<fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">23201468</pub-id></element-citation></ref><ref id="B18"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minca</surname><given-names>E.C.</given-names></name><name><surname>Portier</surname><given-names>B.P.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Lanigan</surname><given-names>C.</given-names></name><name><surname>Farver</surname><given-names>C.F.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>P.C.</given-names></name><name><surname>Arrossi</surname><given-names>V.A.</given-names></name><name><surname>Pennell</surname><given-names>N.A.</given-names></name><name><surname>Tubbs</surname><given-names>R.R.</given-names></name></person-group>
<article-title>ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH</article-title>
<source>J. Mol. Diagn.</source>
<year>2013</year>
<volume>15</volume>
<fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">23499337</pub-id></element-citation></ref><ref id="B19"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar-Sinha</surname><given-names>C.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Landscape of gene fusions in epithelial cancers: seq and ye shall find</article-title>
<source>Genome Med.</source>
<year>2015</year>
<volume>7</volume>
<fpage>129</fpage><pub-id pub-id-type="pmid">26684754</pub-id></element-citation></ref><ref id="B20"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arai</surname><given-names>Y.</given-names></name><name><surname>Totoki</surname><given-names>Y.</given-names></name><name><surname>Hosoda</surname><given-names>F.</given-names></name><name><surname>Shirota</surname><given-names>T.</given-names></name><name><surname>Hama</surname><given-names>N.</given-names></name><name><surname>Nakamura</surname><given-names>H.</given-names></name><name><surname>Ojima</surname><given-names>H.</given-names></name><name><surname>Furuta</surname><given-names>K.</given-names></name><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Okusaka</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma</article-title>
<source>Hepatology</source>
<year>2014</year>
<volume>59</volume>
<fpage>1427</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">24122810</pub-id></element-citation></ref><ref id="B21"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group>
<article-title>RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer</article-title>
<source>J. Clin. Oncol.</source>
<year>2012</year>
<volume>30</volume>
<fpage>4352</fpage><lpage>4359</lpage><pub-id pub-id-type="pmid">23150706</pub-id></element-citation></ref><ref id="B22"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balgobind</surname><given-names>B. V</given-names></name><name><surname>Raimondi</surname><given-names>S.C.</given-names></name><name><surname>Harbott</surname><given-names>J.</given-names></name><name><surname>Zimmermann</surname><given-names>M.</given-names></name><name><surname>Alonzo</surname><given-names>T.A.</given-names></name><name><surname>Auvrignon</surname><given-names>A.</given-names></name><name><surname>Beverloo</surname><given-names>H.B.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name><name><surname>Creutzig</surname><given-names>U.</given-names></name><name><surname>Dworzak</surname><given-names>M.N.</given-names></name><etal/></person-group>
<article-title>Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study</article-title>
<source>Blood</source>
<year>2009</year>
<volume>114</volume>
<fpage>2489</fpage><lpage>2496</lpage><pub-id pub-id-type="pmid">19528532</pub-id></element-citation></ref><ref id="B23"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skapek</surname><given-names>S.X.</given-names></name><name><surname>Anderson</surname><given-names>J.</given-names></name><name><surname>Barr</surname><given-names>F.G.</given-names></name><name><surname>Bridge</surname><given-names>J.A.</given-names></name><name><surname>Gastier-Foster</surname><given-names>J.M.</given-names></name><name><surname>Parham</surname><given-names>D.M.</given-names></name><name><surname>Rudzinski</surname><given-names>E.R.</given-names></name><name><surname>Triche</surname><given-names>T.</given-names></name><name><surname>Hawkins</surname><given-names>D.S.</given-names></name></person-group>
<article-title>PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report</article-title>
<source>Pediatr. Blood Cancer</source>
<year>2013</year>
<volume>60</volume>
<fpage>1411</fpage><lpage>1417</lpage><pub-id pub-id-type="pmid">23526739</pub-id></element-citation></ref><ref id="B24"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duployez</surname><given-names>N.</given-names></name><name><surname>Nibourel</surname><given-names>O.</given-names></name><name><surname>Marceau-Renaut</surname><given-names>A.</given-names></name><name><surname>Willekens</surname><given-names>C.</given-names></name><name><surname>Helevaut</surname><given-names>N.</given-names></name><name><surname>Caillault</surname><given-names>A.</given-names></name><name><surname>Villenet</surname><given-names>C.</given-names></name><name><surname>Celli-Lebras</surname><given-names>K.</given-names></name><name><surname>Boissel</surname><given-names>N.</given-names></name><name><surname>Jourdan</surname><given-names>E.</given-names></name><etal/></person-group>
<article-title>Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA</article-title>
<source>Am. J. Hematol.</source>
<year>2014</year>
<volume>89</volume>
<fpage>610</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">24616160</pub-id></element-citation></ref><ref id="B25"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>J.A.L.</given-names></name><name><surname>O'Brien</surname><given-names>M.A.</given-names></name><name><surname>Hills</surname><given-names>R.K.</given-names></name><name><surname>Daly</surname><given-names>S.B.</given-names></name><name><surname>Wheatley</surname><given-names>K.</given-names></name><name><surname>Burnett</surname><given-names>A.K.</given-names></name></person-group>
<article-title>Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial</article-title>
<source>Blood</source>
<year>2012</year>
<volume>120</volume>
<fpage>2826</fpage><lpage>2835</lpage><pub-id pub-id-type="pmid">22875911</pub-id></element-citation></ref><ref id="B26"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamura</surname><given-names>R.</given-names></name><name><surname>Yoshihara</surname><given-names>K.</given-names></name><name><surname>Yamawaki</surname><given-names>K.</given-names></name><name><surname>Suda</surname><given-names>K.</given-names></name><name><surname>Ishiguro</surname><given-names>T.</given-names></name><name><surname>Adachi</surname><given-names>S.</given-names></name><name><surname>Okuda</surname><given-names>S.</given-names></name><name><surname>Inoue</surname><given-names>I.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.W.</given-names></name><name><surname>Enomoto</surname><given-names>T.</given-names></name></person-group>
<article-title>Novel kinase fusion transcripts found in endometrial cancer</article-title>
<source>Sci. Rep.</source>
<year>2015</year>
<volume>5</volume>
<fpage>18657</fpage><pub-id pub-id-type="pmid">26689674</pub-id></element-citation></ref><ref id="B27"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parker</surname><given-names>B.C.</given-names></name><name><surname>Engels</surname><given-names>M.</given-names></name><name><surname>Annala</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group>
<article-title>Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours</article-title>
<source>J. Pathol.</source>
<year>2014</year>
<volume>232</volume>
<fpage>4</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">24588013</pub-id></element-citation></ref><ref id="B28"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feng</surname><given-names>F.Y.</given-names></name><name><surname>Brenner</surname><given-names>J.C.</given-names></name><name><surname>Hussain</surname><given-names>M.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Molecular pathways: targeting ETS gene fusions in cancer</article-title>
<source>Clin. Cancer Res.</source>
<year>2014</year>
<volume>20</volume>
<fpage>4442</fpage><lpage>4448</lpage><pub-id pub-id-type="pmid">24958807</pub-id></element-citation></ref><ref id="B29"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hochhaus</surname><given-names>A.</given-names></name><name><surname>La&#x000a0;Ros&#x000e9;e</surname><given-names>P.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.C.</given-names></name><name><surname>Ernst</surname><given-names>T.</given-names></name><name><surname>Cross</surname><given-names>N.C.P.</given-names></name></person-group>
<article-title>Impact of BCR-ABL mutations on patients with chronic myeloid leukemia</article-title>
<source>Cell Cycle</source>
<year>2011</year>
<volume>10</volume>
<fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">21220945</pub-id></element-citation></ref><ref id="B30"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hantschel</surname><given-names>O.</given-names></name><name><surname>Grebien</surname><given-names>F.</given-names></name><name><surname>Superti-Furga</surname><given-names>G.</given-names></name></person-group>
<article-title>The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL</article-title>
<source>Cancer Res.</source>
<year>2012</year>
<volume>72</volume>
<fpage>4890</fpage><lpage>4895</lpage><pub-id pub-id-type="pmid">23002203</pub-id></element-citation></ref><ref id="B31"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shaw</surname><given-names>A.T.</given-names></name><name><surname>Kim</surname><given-names>D.-W.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Seto</surname><given-names>T.</given-names></name><name><surname>Crin&#x000f3;</surname><given-names>L.</given-names></name><name><surname>Ahn</surname><given-names>M.-J.</given-names></name><name><surname>De&#x000a0;Pas</surname><given-names>T.</given-names></name><name><surname>Besse</surname><given-names>B.</given-names></name><name><surname>Solomon</surname><given-names>B.J.</given-names></name><name><surname>Blackhall</surname><given-names>F.</given-names></name><etal/></person-group>
<article-title>Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</article-title>
<source>N. Engl. J. Med.</source>
<year>2013</year>
<volume>368</volume>
<fpage>2385</fpage><lpage>2394</lpage><pub-id pub-id-type="pmid">23724913</pub-id></element-citation></ref><ref id="B32"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.-I.J.</given-names></name><name><surname>Kim</surname><given-names>S.S.</given-names></name><name><surname>Ko</surname><given-names>S.</given-names></name><name><surname>In</surname><given-names>Y.-H.</given-names></name><name><surname>Moon</surname><given-names>H.-G.</given-names></name><name><surname>Ahn</surname><given-names>S.K.</given-names></name><name><surname>Kim</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Hwang</surname><given-names>J.-H.</given-names></name><name><surname>Ju</surname><given-names>Y.S.</given-names></name><etal/></person-group>
<article-title>Recurrent fusion transcripts detected by whole-transcriptome sequencing of 120 primary breast cancer samples</article-title>
<source>Genes. Chromosomes Cancer</source>
<year>2015</year>
<volume>54</volume>
<fpage>681</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">26227178</pub-id></element-citation></ref><ref id="B33"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D.R.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Y.-M.</given-names></name><name><surname>Shankar</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Ateeq</surname><given-names>B.</given-names></name><name><surname>Asangani</surname><given-names>I. a</given-names></name><name><surname>Iyer</surname><given-names>M.</given-names></name><name><surname>Maher</surname><given-names>C.A.</given-names></name><name><surname>Grasso</surname><given-names>C.S.</given-names></name><etal/></person-group>
<article-title>Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer</article-title>
<source>Nat. Med.</source>
<year>2011</year>
<volume>17</volume>
<fpage>1646</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">22101766</pub-id></element-citation></ref><ref id="B34"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Edgren</surname><given-names>H.</given-names></name><name><surname>Murumagi</surname><given-names>A.</given-names></name><name><surname>Kangaspeska</surname><given-names>S.</given-names></name><name><surname>Nicorici</surname><given-names>D.</given-names></name><name><surname>Hongisto</surname><given-names>V.</given-names></name><name><surname>Kleivi</surname><given-names>K.</given-names></name><name><surname>Rye</surname><given-names>I.H.</given-names></name><name><surname>Nyberg</surname><given-names>S.</given-names></name><name><surname>Wolf</surname><given-names>M.</given-names></name><name><surname>Borresen-Dale</surname><given-names>A.-L.</given-names></name><etal/></person-group>
<article-title>Identification of fusion genes in breast cancer by paired-end RNA-sequencing</article-title>
<source>Genome Biol.</source>
<year>2011</year>
<volume>12</volume>
<fpage>R6</fpage><pub-id pub-id-type="pmid">21247443</pub-id></element-citation></ref><ref id="B35"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seo</surname><given-names>J.-S.</given-names></name><name><surname>Ju</surname><given-names>Y.S.</given-names></name><name><surname>Lee</surname><given-names>W.-C.</given-names></name><name><surname>Shin</surname><given-names>J.-Y.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name><name><surname>Bleazard</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Jung</surname><given-names>Y.J.</given-names></name><name><surname>Kim</surname><given-names>J.-O.</given-names></name><name><surname>Shin</surname><given-names>J.-Y.</given-names></name><etal/></person-group>
<article-title>The transcriptional landscape and mutational profile of lung adenocarcinoma</article-title>
<source>Genome Res.</source>
<year>2012</year>
<volume>22</volume>
<fpage>2109</fpage><lpage>2119</lpage><pub-id pub-id-type="pmid">22975805</pub-id></element-citation></ref><ref id="B36"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teles&#x000a0;Alves</surname><given-names>I.</given-names></name><name><surname>Hartjes</surname><given-names>T.</given-names></name><name><surname>McClellan</surname><given-names>E.</given-names></name><name><surname>Hiltemann</surname><given-names>S.</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>R.</given-names></name><name><surname>Dits</surname><given-names>N.</given-names></name><name><surname>Temanni</surname><given-names>M.R.</given-names></name><name><surname>Janssen</surname><given-names>B.</given-names></name><name><surname>van&#x000a0;Workum</surname><given-names>W.</given-names></name><name><surname>van&#x000a0;der&#x000a0;Spek</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer</article-title>
<source>Oncogene</source>
<year>2015</year>
<volume>34</volume>
<fpage>568</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">24488012</pub-id></element-citation></ref><ref id="B37"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pflueger</surname><given-names>D.</given-names></name><name><surname>Terry</surname><given-names>S.</given-names></name><name><surname>Sboner</surname><given-names>A.</given-names></name><name><surname>Habegger</surname><given-names>L.</given-names></name><name><surname>Esgueva</surname><given-names>R.</given-names></name><name><surname>Lin</surname><given-names>P.-C.</given-names></name><name><surname>Svensson</surname><given-names>M.A.</given-names></name><name><surname>Kitabayashi</surname><given-names>N.</given-names></name><name><surname>Moss</surname><given-names>B.J.</given-names></name><name><surname>MacDonald</surname><given-names>T.Y.</given-names></name><etal/></person-group>
<article-title>Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing</article-title>
<source>Genome Res.</source>
<year>2011</year>
<volume>21</volume>
<fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">21036922</pub-id></element-citation></ref><ref id="B38"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kannan</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ittmann</surname><given-names>M.M.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Yen</surname><given-names>L.</given-names></name></person-group>
<article-title>Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing</article-title>
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2011</year>
<volume>108</volume>
<fpage>9172</fpage><lpage>9177</lpage><pub-id pub-id-type="pmid">21571633</pub-id></element-citation></ref><ref id="B39"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.-H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zuo</surname><given-names>Z.-H.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Tseng</surname><given-names>G.C.</given-names></name><name><surname>Yu</surname><given-names>Y.P.</given-names></name></person-group>
<article-title>Discovery and classification of fusion transcripts in prostate cancer and normal prostate tissue</article-title>
<source>Am. J. Pathol.</source>
<year>2015</year>
<volume>185</volume>
<fpage>1834</fpage><lpage>1845</lpage><pub-id pub-id-type="pmid">25963990</pub-id></element-citation></ref><ref id="B40"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steidl</surname><given-names>C.</given-names></name><name><surname>Shah</surname><given-names>S.P.</given-names></name><name><surname>Woolcock</surname><given-names>B.W.</given-names></name><name><surname>Rui</surname><given-names>L.</given-names></name><name><surname>Kawahara</surname><given-names>M.</given-names></name><name><surname>Farinha</surname><given-names>P.</given-names></name><name><surname>Johnson</surname><given-names>N.A.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Telenius</surname><given-names>A.</given-names></name><name><surname>Neriah</surname><given-names>S. Ben</given-names></name><etal/></person-group>
<article-title>MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers</article-title>
<source>Nature</source>
<year>2011</year>
<volume>471</volume>
<fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">21368758</pub-id></element-citation></ref><ref id="B41"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shah</surname><given-names>N.</given-names></name><name><surname>Lankerovich</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Yoon</surname><given-names>J.-G.</given-names></name><name><surname>Schroeder</surname><given-names>B.</given-names></name><name><surname>Foltz</surname><given-names>G.</given-names></name></person-group>
<article-title>Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data</article-title>
<source>BMC Genomics</source>
<year>2013</year>
<volume>14</volume>
<fpage>818</fpage><pub-id pub-id-type="pmid">24261984</pub-id></element-citation></ref><ref id="B42"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Wyatt</surname><given-names>A.W.</given-names></name><name><surname>Lapuk</surname><given-names>A. V</given-names></name><name><surname>McPherson</surname><given-names>A.</given-names></name><name><surname>McConeghy</surname><given-names>B.J.</given-names></name><name><surname>Bell</surname><given-names>R.H.</given-names></name><name><surname>Anderson</surname><given-names>S.</given-names></name><name><surname>Haegert</surname><given-names>A.</given-names></name><name><surname>Brahmbhatt</surname><given-names>S.</given-names></name><name><surname>Shukin</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer</article-title>
<source>J. Pathol.</source>
<year>2012</year>
<volume>227</volume>
<fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">22294438</pub-id></element-citation></ref><ref id="B43"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parker</surname><given-names>M.</given-names></name><name><surname>Mohankumar</surname><given-names>K.M.</given-names></name><name><surname>Punchihewa</surname><given-names>C.</given-names></name><name><surname>Weinlich</surname><given-names>R.</given-names></name><name><surname>Dalton</surname><given-names>J.D.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>R.</given-names></name><name><surname>Tatevossian</surname><given-names>R.G.</given-names></name><name><surname>Phoenix</surname><given-names>T.N.</given-names></name><name><surname>Thiruvenkatam</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>C11orf95-RELA fusions drive oncogenic NF-&#x003ba;B signalling in ependymoma</article-title>
<source>Nature</source>
<year>2014</year>
<volume>506</volume>
<fpage>451</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">24553141</pub-id></element-citation></ref><ref id="B44"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Honeyman</surname><given-names>J.N.</given-names></name><name><surname>Simon</surname><given-names>E.P.</given-names></name><name><surname>Robine</surname><given-names>N.</given-names></name><name><surname>Chiaroni-Clarke</surname><given-names>R.</given-names></name><name><surname>Darcy</surname><given-names>D.G.</given-names></name><name><surname>Lim</surname><given-names>I.I.P.</given-names></name><name><surname>Gleason</surname><given-names>C.E.</given-names></name><name><surname>Murphy</surname><given-names>J.M.</given-names></name><name><surname>Rosenberg</surname><given-names>B.R.</given-names></name><name><surname>Teegan</surname><given-names>L.</given-names></name><etal/></person-group>
<article-title>Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma</article-title>
<source>Science</source>
<year>2014</year>
<volume>343</volume>
<fpage>1010</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">24578576</pub-id></element-citation></ref><ref id="B45"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>H&#x000f6;glund</surname><given-names>M.</given-names></name><name><surname>Frigyesi</surname><given-names>A.</given-names></name><name><surname>Mitelman</surname><given-names>F.</given-names></name></person-group>
<article-title>A gene fusion network in human neoplasia</article-title>
<source>Oncogene</source>
<year>2006</year>
<volume>25</volume>
<fpage>2674</fpage><lpage>2678</lpage><pub-id pub-id-type="pmid">16331252</pub-id></element-citation></ref><ref id="B46"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortiz&#x000a0;de&#x000a0;Mend&#x000ed;bil</surname><given-names>I.</given-names></name><name><surname>Vizmanos</surname><given-names>J.L.</given-names></name><name><surname>Novo</surname><given-names>F.J.</given-names></name></person-group>
<article-title>Signatures of selection in fusion transcripts resulting from chromosomal translocations in human cancer</article-title>
<source>PLoS One</source>
<year>2009</year>
<volume>4</volume>
<fpage>e4805</fpage><pub-id pub-id-type="pmid">19279687</pub-id></element-citation></ref><ref id="B47"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shugay</surname><given-names>M.</given-names></name><name><surname>Ortiz&#x000a0;de&#x000a0;Mend&#x000ed;bil</surname><given-names>I.</given-names></name><name><surname>Vizmanos</surname><given-names>J.L.</given-names></name><name><surname>Novo</surname><given-names>F.J.</given-names></name></person-group>
<article-title>Genomic hallmarks of genes involved in chromosomal translocations in hematological cancer</article-title>
<source>PLoS Comput. Biol.</source>
<year>2012</year>
<volume>8</volume>
<fpage>e1002797</fpage><pub-id pub-id-type="pmid">23236267</pub-id></element-citation></ref><ref id="B48"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>E.H.Y.</given-names></name><name><surname>Hsieh</surname><given-names>J.J.D.</given-names></name></person-group>
<article-title>MLL fusions: pathways to leukemia</article-title>
<source>Cancer Biol. Ther.</source>
<year>2009</year>
<volume>8</volume>
<fpage>1204</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">19729989</pub-id></element-citation></ref><ref id="B49"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.-S.</given-names></name><name><surname>Prensner</surname><given-names>J.R.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Dhanasekaran</surname><given-names>S.M.</given-names></name><name><surname>Ponnala</surname><given-names>R.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Varambally</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>D.G.</given-names></name><etal/></person-group>
<article-title>An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer</article-title>
<source>Nat. Biotechnol.</source>
<year>2009</year>
<volume>27</volume>
<fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">19881495</pub-id></element-citation></ref><ref id="B50"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.-M.</given-names></name><name><surname>Su</surname><given-names>F.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Khazanov</surname><given-names>N.</given-names></name><name><surname>Ateeq</surname><given-names>B.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Lonigro</surname><given-names>R.J.</given-names></name><name><surname>Vats</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Lin</surname><given-names>S.-F.</given-names></name><etal/></person-group>
<article-title>Identification of targetable FGFR gene fusions in diverse cancers</article-title>
<source>Cancer Discov.</source>
<year>2013</year>
<volume>3</volume>
<fpage>636</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">23558953</pub-id></element-citation></ref><ref id="B51"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>M.S.</given-names></name><name><surname>Stojanov</surname><given-names>P.</given-names></name><name><surname>Polak</surname><given-names>P.</given-names></name><name><surname>Kryukov</surname><given-names>G. V</given-names></name><name><surname>Cibulskis</surname><given-names>K.</given-names></name><name><surname>Sivachenko</surname><given-names>A.</given-names></name><name><surname>Carter</surname><given-names>S.L.</given-names></name><name><surname>Stewart</surname><given-names>C.</given-names></name><name><surname>Mermel</surname><given-names>C.H.</given-names></name><name><surname>Roberts</surname><given-names>S.a</given-names></name><etal/></person-group>
<article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title>
<source>Nature</source>
<year>2013</year>
<volume>499</volume>
<fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">23770567</pub-id></element-citation></ref><ref id="B52"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Alexander</surname><given-names>R.E.</given-names></name><name><surname>Maclennan</surname><given-names>G.T.</given-names></name><name><surname>Cummings</surname><given-names>O.W.</given-names></name><name><surname>Montironi</surname><given-names>R.</given-names></name><name><surname>Lopez-Beltran</surname><given-names>A.</given-names></name><name><surname>Cramer</surname><given-names>H.M.</given-names></name><name><surname>Davidson</surname><given-names>D.D.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group>
<article-title>Molecular pathology of lung cancer: key to personalized medicine</article-title>
<source>Mod. Pathol.</source>
<year>2012</year>
<volume>25</volume>
<fpage>347</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">22282308</pub-id></element-citation></ref><ref id="B53"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Shankar</surname><given-names>S.</given-names></name><name><surname>Deroo</surname><given-names>S.</given-names></name><name><surname>Iyer</surname><given-names>M.K.</given-names></name><name><surname>Palanisamy</surname><given-names>N.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name><name><surname>Kumar-Sinha</surname><given-names>C.</given-names></name></person-group>
<article-title>Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer</article-title>
<source>Neoplasia</source>
<year>2012</year>
<volume>14</volume>
<fpage>702</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">22952423</pub-id></element-citation></ref><ref id="B54"><label>54.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stransky</surname><given-names>N.</given-names></name><name><surname>Cerami</surname><given-names>E.</given-names></name><name><surname>Schalm</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J.L.</given-names></name><name><surname>Lengauer</surname><given-names>C.</given-names></name></person-group>
<article-title>The landscape of kinase fusions in cancer</article-title>
<source>Nat. Commun.</source>
<year>2014</year>
<volume>5</volume>
<fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="B55"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabbitts</surname><given-names>T.H.</given-names></name></person-group>
<article-title>Commonality but diversity in cancer gene fusions</article-title>
<source>Cell</source>
<year>2009</year>
<volume>137</volume>
<fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">19410533</pub-id></element-citation></ref><ref id="B56"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>F.</given-names></name><name><surname>Johansson</surname><given-names>B.</given-names></name><name><surname>Mertens</surname><given-names>F.</given-names></name></person-group>
<article-title>Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer</article-title>
<source>Nat. Genet.</source>
<year>2004</year>
<volume>36</volume>
<fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">15054488</pub-id></element-citation></ref><ref id="B57"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davare</surname><given-names>M.A.</given-names></name><name><surname>Tognon</surname><given-names>C.E.</given-names></name></person-group>
<article-title>Detecting and targetting oncogenic fusion proteins in the genomic era</article-title>
<source>Biol. Cell</source>
<year>2015</year>
<volume>107</volume>
<fpage>111</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">25631473</pub-id></element-citation></ref><ref id="B58"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shaw</surname><given-names>A.T.</given-names></name><name><surname>Hsu</surname><given-names>P.P.</given-names></name><name><surname>Awad</surname><given-names>M.M.</given-names></name><name><surname>Engelman</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Tyrosine kinase gene rearrangements in epithelial malignancies</article-title>
<source>Nat. Rev. Cancer</source>
<year>2013</year>
<volume>13</volume>
<fpage>772</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">24132104</pub-id></element-citation></ref><ref id="B59"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Helin</surname><given-names>K.</given-names></name><name><surname>Dhanak</surname><given-names>D.</given-names></name></person-group>
<article-title>Chromatin proteins and modifications as drug targets</article-title>
<source>Nature</source>
<year>2013</year>
<volume>502</volume>
<fpage>480</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">24153301</pub-id></element-citation></ref><ref id="B60"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ross</surname><given-names>J.S.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Chmielecki</surname><given-names>J.</given-names></name><name><surname>Gay</surname><given-names>L.</given-names></name><name><surname>Johnson</surname><given-names>A.</given-names></name><name><surname>Chudnovsky</surname><given-names>J.</given-names></name><name><surname>Yelensky</surname><given-names>R.</given-names></name><name><surname>Lipson</surname><given-names>D.</given-names></name><name><surname>Ali</surname><given-names>S.M.</given-names></name><name><surname>Elvin</surname><given-names>J.A.</given-names></name><etal/></person-group>
<article-title>The distribution of BRAF gene fusions in solid tumors and response to targeted therapy</article-title>
<source>Int. J. Cancer</source>
<year>2016</year>
<volume>138</volume>
<fpage>881</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">26314551</pub-id></element-citation></ref><ref id="B61"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>S. V</given-names></name><name><surname>Hurst</surname><given-names>C.D.</given-names></name><name><surname>Knowles</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Oncogenic FGFR3 gene fusions in bladder cancer</article-title>
<source>Hum. Mol. Genet.</source>
<year>2013</year>
<volume>22</volume>
<fpage>795</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">23175443</pub-id></element-citation></ref><ref id="B62"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Acquaviva</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Jimenez</surname><given-names>J.-P.</given-names></name><name><surname>Nagai</surname><given-names>M.</given-names></name><name><surname>Sang</surname><given-names>J.</given-names></name><name><surname>Sequeira</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>D.L.</given-names></name><name><surname>Ogawa</surname><given-names>L.S.</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism</article-title>
<source>Mol. Cancer Res.</source>
<year>2014</year>
<volume>12</volume>
<fpage>1042</fpage><lpage>1054</lpage><pub-id pub-id-type="pmid">24784839</pub-id></element-citation></ref><ref id="B63"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Tanizaki</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Aref</surname><given-names>A.R.</given-names></name><name><surname>Rusan</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>S.-J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ercan</surname><given-names>D.</given-names></name><name><surname>Liao</surname><given-names>R.G.</given-names></name><etal/></person-group>
<article-title>Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</article-title>
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2014</year>
<volume>111</volume>
<fpage>E4869</fpage><lpage>E4877</lpage><pub-id pub-id-type="pmid">25349422</pub-id></element-citation></ref><ref id="B64"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Touat</surname><given-names>M.</given-names></name><name><surname>Ileana</surname><given-names>E.</given-names></name><name><surname>Postel-Vinay</surname><given-names>S.</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F.</given-names></name><name><surname>Soria</surname><given-names>J.-C.</given-names></name></person-group>
<article-title>Targeting FGFR signaling in cancer</article-title>
<source>Clin. Cancer Res.</source>
<year>2015</year>
<volume>21</volume>
<fpage>2684</fpage><lpage>2694</lpage><pub-id pub-id-type="pmid">26078430</pub-id></element-citation></ref><ref id="B65"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerber</surname><given-names>D.E.</given-names></name><name><surname>Minna</surname><given-names>J.D.</given-names></name></person-group>
<article-title>ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time</article-title>
<source>Cancer Cell</source>
<year>2010</year>
<volume>18</volume>
<fpage>548</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">21156280</pub-id></element-citation></ref><ref id="B66"><label>66.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soda</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>Y.L.</given-names></name><name><surname>Enomoto</surname><given-names>M.</given-names></name><name><surname>Takada</surname><given-names>S.</given-names></name><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Ishikawa</surname><given-names>S.</given-names></name><name><surname>Fujiwara</surname><given-names>S.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Kurashina</surname><given-names>K.</given-names></name><name><surname>Hatanaka</surname><given-names>H.</given-names></name><etal/></person-group>
<article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title>
<source>Nature</source>
<year>2007</year>
<volume>448</volume>
<fpage>561</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">17625570</pub-id></element-citation></ref><ref id="B67"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koivunen</surname><given-names>J.P.</given-names></name><name><surname>Mermel</surname><given-names>C.</given-names></name><name><surname>Zejnullahu</surname><given-names>K.</given-names></name><name><surname>Murphy</surname><given-names>C.</given-names></name><name><surname>Lifshits</surname><given-names>E.</given-names></name><name><surname>Holmes</surname><given-names>A.J.</given-names></name><name><surname>Choi</surname><given-names>H.G.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Chiang</surname><given-names>D.</given-names></name><name><surname>Thomas</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer</article-title>
<source>Clin. Cancer Res.</source>
<year>2008</year>
<volume>14</volume>
<fpage>4275</fpage><lpage>4283</lpage><pub-id pub-id-type="pmid">18594010</pub-id></element-citation></ref><ref id="B68"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scagliotti</surname><given-names>G.</given-names></name><name><surname>Stahel</surname><given-names>R.A.</given-names></name><name><surname>Rosell</surname><given-names>R.</given-names></name><name><surname>Thatcher</surname><given-names>N.</given-names></name><name><surname>Soria</surname><given-names>J.-C.</given-names></name></person-group>
<article-title>ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development</article-title>
<source>Eur. J. Cancer</source>
<year>2012</year>
<volume>48</volume>
<fpage>961</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">22397764</pub-id></element-citation></ref><ref id="B69"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Rodig</surname><given-names>S.J.</given-names></name><name><surname>Chirieac</surname><given-names>L.R.</given-names></name><name><surname>J&#x000e4;nne</surname><given-names>P.A.</given-names></name></person-group>
<article-title>The biology and treatment of EML4-ALK non-small cell lung cancer</article-title>
<source>Eur. J. Cancer</source>
<year>2010</year>
<volume>46</volume>
<fpage>1773</fpage><lpage>1780</lpage><pub-id pub-id-type="pmid">20418096</pub-id></element-citation></ref><ref id="B70"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shaw</surname><given-names>A.T.</given-names></name><name><surname>Ou</surname><given-names>S.-H.I.</given-names></name><name><surname>Bang</surname><given-names>Y.-J.</given-names></name><name><surname>Camidge</surname><given-names>D.R.</given-names></name><name><surname>Solomon</surname><given-names>B.J.</given-names></name><name><surname>Salgia</surname><given-names>R.</given-names></name><name><surname>Riely</surname><given-names>G.J.</given-names></name><name><surname>Varella-Garcia</surname><given-names>M.</given-names></name><name><surname>Shapiro</surname><given-names>G.I.</given-names></name><name><surname>Costa</surname><given-names>D.B.</given-names></name><etal/></person-group>
<article-title>Crizotinib in ROS1-rearranged non-small-cell lung cancer</article-title>
<source>N. Engl. J. Med.</source>
<year>2014</year>
<volume>371</volume>
<fpage>1963</fpage><lpage>1971</lpage><pub-id pub-id-type="pmid">25264305</pub-id></element-citation></ref><ref id="B71"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bergethon</surname><given-names>K.</given-names></name><name><surname>Shaw</surname><given-names>A.T.</given-names></name><name><surname>Ou</surname><given-names>S.-H.I.</given-names></name><name><surname>Katayama</surname><given-names>R.</given-names></name><name><surname>Lovly</surname><given-names>C.M.</given-names></name><name><surname>McDonald</surname><given-names>N.T.</given-names></name><name><surname>Massion</surname><given-names>P.P.</given-names></name><name><surname>Siwak-Tapp</surname><given-names>C.</given-names></name><name><surname>Gonzalez</surname><given-names>A.</given-names></name><name><surname>Fang</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>ROS1 rearrangements define a unique molecular class of lung cancers</article-title>
<source>J. Clin. Oncol.</source>
<year>2012</year>
<volume>30</volume>
<fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">22215748</pub-id></element-citation></ref><ref id="B72"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilson</surname><given-names>F.H.</given-names></name><name><surname>Johannessen</surname><given-names>C.M.</given-names></name><name><surname>Piccioni</surname><given-names>F.</given-names></name><name><surname>Tamayo</surname><given-names>P.</given-names></name><name><surname>Kim</surname><given-names>J.W.</given-names></name><name><surname>Van&#x000a0;Allen</surname><given-names>E.M.</given-names></name><name><surname>Corsello</surname><given-names>S.M.</given-names></name><name><surname>Capelletti</surname><given-names>M.</given-names></name><name><surname>Calles</surname><given-names>A.</given-names></name><name><surname>Butaney</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>A functional landscape of resistance to ALK inhibition in lung cancer</article-title>
<source>Cancer Cell</source>
<year>2015</year>
<volume>27</volume>
<fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">25759024</pub-id></element-citation></ref><ref id="B73"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y.L.</given-names></name><name><surname>Soda</surname><given-names>M.</given-names></name><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Ueno</surname><given-names>T.</given-names></name><name><surname>Takashima</surname><given-names>J.</given-names></name><name><surname>Nakajima</surname><given-names>T.</given-names></name><name><surname>Yatabe</surname><given-names>Y.</given-names></name><name><surname>Takeuchi</surname><given-names>K.</given-names></name><name><surname>Hamada</surname><given-names>T.</given-names></name><name><surname>Haruta</surname><given-names>H.</given-names></name><etal/></person-group>
<article-title>EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</article-title>
<source>N. Engl. J. Med.</source>
<year>2010</year>
<volume>363</volume>
<fpage>1734</fpage><lpage>1739</lpage><pub-id pub-id-type="pmid">20979473</pub-id></element-citation></ref><ref id="B74"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katayama</surname><given-names>R.</given-names></name><name><surname>Shaw</surname><given-names>A.T.</given-names></name><name><surname>Khan</surname><given-names>T.M.</given-names></name><name><surname>Mino-Kenudson</surname><given-names>M.</given-names></name><name><surname>Solomon</surname><given-names>B.J.</given-names></name><name><surname>Halmos</surname><given-names>B.</given-names></name><name><surname>Jessop</surname><given-names>N.A.</given-names></name><name><surname>Wain</surname><given-names>J.C.</given-names></name><name><surname>Yeo</surname><given-names>A.T.</given-names></name><name><surname>Benes</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers</article-title>
<source>Sci. Transl. Med.</source>
<year>2012</year>
<volume>4</volume>
<fpage>120ra17</fpage></element-citation></ref><ref id="B75"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>T.M.</given-names></name><name><surname>Kim</surname><given-names>D.-W.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Keam</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>S.-H.</given-names></name><name><surname>Heo</surname><given-names>D.S.</given-names></name></person-group>
<article-title>Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer</article-title>
<source>Clin. Cancer Res.</source>
<year>2015</year>
<volume>21</volume>
<fpage>2379</fpage><lpage>2387</lpage><pub-id pub-id-type="pmid">25688157</pub-id></element-citation></ref><ref id="B76"><label>76.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katayama</surname><given-names>R.</given-names></name><name><surname>Khan</surname><given-names>T.M.</given-names></name><name><surname>Benes</surname><given-names>C.</given-names></name><name><surname>Lifshits</surname><given-names>E.</given-names></name><name><surname>Ebi</surname><given-names>H.</given-names></name><name><surname>Rivera</surname><given-names>V.M.</given-names></name><name><surname>Shakespeare</surname><given-names>W.C.</given-names></name><name><surname>Iafrate</surname><given-names>A.J.</given-names></name><name><surname>Engelman</surname><given-names>J.A.</given-names></name><name><surname>Shaw</surname><given-names>A.T.</given-names></name></person-group>
<article-title>Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</article-title>
<source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2011</year>
<volume>108</volume>
<fpage>7535</fpage><lpage>7540</lpage><pub-id pub-id-type="pmid">21502504</pub-id></element-citation></ref><ref id="B77"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ye</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Jing</surname><given-names>P.</given-names></name><name><surname>Chang</surname><given-names>N.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group>
<article-title>ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance</article-title>
<source>Oncotarget</source>
<year>2016</year>
<volume>7</volume>
<fpage>12289</fpage><lpage>12304</lpage><pub-id pub-id-type="pmid">26802023</pub-id></element-citation></ref><ref id="B78"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katayama</surname><given-names>R.</given-names></name><name><surname>Kobayashi</surname><given-names>Y.</given-names></name><name><surname>Friboulet</surname><given-names>L.</given-names></name><name><surname>Lockerman</surname><given-names>E.L.</given-names></name><name><surname>Koike</surname><given-names>S.</given-names></name><name><surname>Shaw</surname><given-names>A.T.</given-names></name><name><surname>Engelman</surname><given-names>J.A.</given-names></name><name><surname>Fujita</surname><given-names>N.</given-names></name></person-group>
<article-title>Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer</article-title>
<source>Clin. Cancer Res.</source>
<year>2015</year>
<volume>21</volume>
<fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">25351743</pub-id></element-citation></ref><ref id="B79"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>I.B.</given-names></name><name><surname>De&#x000a0;Langen</surname><given-names>A.J.</given-names></name><name><surname>Honeywell</surname><given-names>R.J.</given-names></name><name><surname>Giovannetti</surname><given-names>E.</given-names></name><name><surname>Peters</surname><given-names>G.J.</given-names></name></person-group>
<article-title>Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib</article-title>
<source>Expert Rev. Anticancer Ther.</source>
<year>2016</year>
<volume>16</volume>
<fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">26654422</pub-id></element-citation></ref><ref id="B80"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hallberg</surname><given-names>B.</given-names></name><name><surname>Palmer</surname><given-names>R.H.</given-names></name></person-group>
<article-title>Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</article-title>
<source>Nat. Rev. Cancer</source>
<year>2013</year>
<volume>13</volume>
<fpage>685</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">24060861</pub-id></element-citation></ref><ref id="B81"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mari&#x000f1;o-Enr&#x000ed;quez</surname><given-names>A.</given-names></name><name><surname>Dal&#x000a0;Cin</surname><given-names>P.</given-names></name></person-group>
<article-title>ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages</article-title>
<source>Cancer Genet.</source>
<year>2013</year>
<volume>206</volume>
<fpage>357</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">24091028</pub-id></element-citation></ref><ref id="B82"><label>82.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gross</surname><given-names>S.</given-names></name><name><surname>Rahal</surname><given-names>R.</given-names></name><name><surname>Stransky</surname><given-names>N.</given-names></name><name><surname>Lengauer</surname><given-names>C.</given-names></name><name><surname>Hoeflich</surname><given-names>K.P.</given-names></name></person-group>
<article-title>Targeting cancer with kinase inhibitors</article-title>
<source>J. Clin. Invest.</source>
<year>2015</year>
<volume>125</volume>
<fpage>1780</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">25932675</pub-id></element-citation></ref><ref id="B83"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tognon</surname><given-names>C.E.</given-names></name><name><surname>Somasiri</surname><given-names>A.M.</given-names></name><name><surname>Evdokimova</surname><given-names>V.E.</given-names></name><name><surname>Trigo</surname><given-names>G.</given-names></name><name><surname>Uy</surname><given-names>E.E.</given-names></name><name><surname>Melnyk</surname><given-names>N.</given-names></name><name><surname>Carboni</surname><given-names>J.M.</given-names></name><name><surname>Gottardis</surname><given-names>M.M.</given-names></name><name><surname>Roskelley</surname><given-names>C.D.</given-names></name><name><surname>Pollak</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway</article-title>
<source>Cancer Res.</source>
<year>2011</year>
<volume>71</volume>
<fpage>1060</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">21148487</pub-id></element-citation></ref><ref id="B84"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frenkel-Morgenstern</surname><given-names>M.</given-names></name><name><surname>Lacroix</surname><given-names>V.</given-names></name><name><surname>Ezkurdia</surname><given-names>I.</given-names></name><name><surname>Levin</surname><given-names>Y.</given-names></name><name><surname>Gabashvili</surname><given-names>A.</given-names></name><name><surname>Prilusky</surname><given-names>J.</given-names></name><name><surname>Pozo</surname><given-names>A.</given-names></name><name><surname>Tress</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>R.</given-names></name><name><surname>Guigo</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>Chimeras taking shape: potential functions of proteins encoded by chimeric RNA transcripts</article-title>
<source>Genome Res.</source>
<year>2012</year>
<volume>22</volume>
<fpage>1231</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">22588898</pub-id></element-citation></ref><ref id="B85"><label>85.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roukos</surname><given-names>V.</given-names></name><name><surname>Misteli</surname><given-names>T.</given-names></name></person-group>
<article-title>The biogenesis of chromosome translocations</article-title>
<source>Nat. Cell Biol.</source>
<year>2014</year>
<volume>16</volume>
<fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">24691255</pub-id></element-citation></ref><ref id="B86"><label>86.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abate</surname><given-names>F.</given-names></name><name><surname>Zairis</surname><given-names>S.</given-names></name><name><surname>Ficarra</surname><given-names>E.</given-names></name><name><surname>Acquaviva</surname><given-names>A.</given-names></name><name><surname>Wiggins</surname><given-names>C.H.</given-names></name><name><surname>Frattini</surname><given-names>V.</given-names></name><name><surname>Lasorella</surname><given-names>A.</given-names></name><name><surname>Iavarone</surname><given-names>A.</given-names></name><name><surname>Inghirami</surname><given-names>G.</given-names></name><name><surname>Rabadan</surname><given-names>R.</given-names></name></person-group>
<article-title>Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer</article-title>
<source>BMC Syst. Biol.</source>
<year>2014</year>
<volume>8</volume>
<fpage>97</fpage><pub-id pub-id-type="pmid">25183062</pub-id></element-citation></ref><ref id="B87"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hegyi</surname><given-names>H.</given-names></name><name><surname>Buday</surname><given-names>L.</given-names></name><name><surname>Tompa</surname><given-names>P.</given-names></name></person-group>
<article-title>Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins</article-title>
<source>PLoS Comput. Biol.</source>
<year>2009</year>
<volume>5</volume>
<fpage>e1000552</fpage><pub-id pub-id-type="pmid">19888473</pub-id></element-citation></ref><ref id="B88"><label>88.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korla</surname><given-names>P.K.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>C.-H.</given-names></name><name><surname>Tsai</surname><given-names>J.J.P.</given-names></name><name><surname>Liu</surname><given-names>Y.-H.</given-names></name><name><surname>Kurubanjerdjit</surname><given-names>N.</given-names></name><name><surname>Hsieh</surname><given-names>W.-T.</given-names></name><name><surname>Chen</surname><given-names>H.-Y.</given-names></name><name><surname>Ng</surname><given-names>K.-L.</given-names></name></person-group>
<article-title>FARE-CAFE: a database of functional and regulatory elements of cancer-associated fusion events</article-title>
<source>Database (Oxford)</source>
<year>2015</year>
<volume>2015</volume>
<fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="B89"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frenkel-Morgenstern</surname><given-names>M.</given-names></name><name><surname>Valencia</surname><given-names>A.</given-names></name></person-group>
<article-title>Novel domain combinations in proteins encoded by chimeric transcripts</article-title>
<source>Bioinformatics</source>
<year>2012</year>
<volume>28</volume>
<fpage>i67</fpage><lpage>i74</lpage><pub-id pub-id-type="pmid">22689780</pub-id></element-citation></ref><ref id="B90"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Sasaki</surname><given-names>S.</given-names></name><name><surname>Morita</surname><given-names>H.</given-names></name><name><surname>Oki</surname><given-names>Y.</given-names></name><name><surname>Turiya</surname><given-names>D.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Misawa</surname><given-names>H.</given-names></name><name><surname>Ishizuka</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>H.</given-names></name></person-group>
<article-title>The role of the amino-terminal domain in the interaction of unliganded peroxisome proliferator-activated receptor gamma-2 with nuclear receptor co-repressor</article-title>
<source>J. Mol. Endocrinol.</source>
<year>2010</year>
<volume>45</volume>
<fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">20587609</pub-id></element-citation></ref><ref id="B91"><label>91.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>D.-E.</given-names></name></person-group>
<article-title>RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis</article-title>
<source>Front. Biosci. (Landmark Ed.</source>
<year>2012</year>
<volume>17</volume>
<fpage>1120</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">22201794</pub-id></element-citation></ref><ref id="B92"><label>92.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peterson</surname><given-names>L.F.</given-names></name><name><surname>Zhang</surname><given-names>D.-E.</given-names></name></person-group>
<article-title>The 8;21 translocation in leukemogenesis</article-title>
<source>Oncogene</source>
<year>2004</year>
<volume>23</volume>
<fpage>4255</fpage><lpage>4262</lpage><pub-id pub-id-type="pmid">15156181</pub-id></element-citation></ref><ref id="B93"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ptasinska</surname><given-names>A.</given-names></name><name><surname>Assi</surname><given-names>S.A.</given-names></name><name><surname>Mannari</surname><given-names>D.</given-names></name><name><surname>James</surname><given-names>S.R.</given-names></name><name><surname>Williamson</surname><given-names>D.</given-names></name><name><surname>Dunne</surname><given-names>J.</given-names></name><name><surname>Hoogenkamp</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Care</surname><given-names>M.</given-names></name><name><surname>McNeill</surname><given-names>H.</given-names></name><etal/></person-group>
<article-title>Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding</article-title>
<source>Leukemia</source>
<year>2012</year>
<volume>26</volume>
<fpage>1829</fpage><lpage>1841</lpage><pub-id pub-id-type="pmid">22343733</pub-id></element-citation></ref><ref id="B94"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pawson</surname><given-names>T.</given-names></name><name><surname>Warner</surname><given-names>N.</given-names></name></person-group>
<article-title>Oncogenic re-wiring of cellular signaling pathways</article-title>
<source>Oncogene</source>
<year>2007</year>
<volume>26</volume>
<fpage>1268</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">17322911</pub-id></element-citation></ref><ref id="B95"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shugay</surname><given-names>M.</given-names></name><name><surname>Ortiz&#x000a0;de&#x000a0;Mend&#x000ed;bil</surname><given-names>I.</given-names></name><name><surname>Vizmanos</surname><given-names>J.L.</given-names></name><name><surname>Novo</surname><given-names>F.J.</given-names></name></person-group>
<article-title>Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions</article-title>
<source>Bioinformatics</source>
<year>2013</year>
<volume>29</volume>
<fpage>2539</fpage><lpage>2546</lpage><pub-id pub-id-type="pmid">23956304</pub-id></element-citation></ref><ref id="B96"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benzekry</surname><given-names>S.</given-names></name><name><surname>Tuszynski</surname><given-names>J.A.</given-names></name><name><surname>Rietman</surname><given-names>E.A.</given-names></name><name><surname>Lakka&#x000a0;Klement</surname><given-names>G.</given-names></name></person-group>
<article-title>Design principles for cancer therapy guided by changes in complexity of protein-protein interaction networks</article-title>
<source>Biol. Direct</source>
<year>2015</year>
<volume>10</volume>
<fpage>32</fpage><pub-id pub-id-type="pmid">26018239</pub-id></element-citation></ref><ref id="B97"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hajingabo</surname><given-names>L.J.L.</given-names></name><name><surname>Daakour</surname><given-names>S.</given-names></name><name><surname>Martin</surname><given-names>M.</given-names></name><name><surname>Grausenburger</surname><given-names>R.</given-names></name><name><surname>Panzer-Gr&#x000fc;mayer</surname><given-names>R.</given-names></name><name><surname>Dequiedt</surname><given-names>F.</given-names></name><name><surname>Simonis</surname><given-names>N.</given-names></name><name><surname>Twizere</surname><given-names>J.-C.</given-names></name><name><surname>Panzer-Grumayer</surname><given-names>R.</given-names></name><name><surname>Dequiedt</surname><given-names>F.</given-names></name><etal/></person-group>
<article-title>Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia</article-title>
<source>Mol. Biol. Cell</source>
<year>2014</year>
<volume>25</volume>
<fpage>3973</fpage><lpage>3985</lpage><pub-id pub-id-type="pmid">25273558</pub-id></element-citation></ref><ref id="B98"><label>98.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Stein</surname><given-names>L.</given-names></name></person-group>
<article-title>A human functional protein interaction network and its application to cancer data analysis</article-title>
<source>Genome Biol.</source>
<year>2010</year>
<volume>11</volume>
<fpage>R53</fpage><pub-id pub-id-type="pmid">20482850</pub-id></element-citation></ref><ref id="B99"><label>99.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ciriello</surname><given-names>G.</given-names></name><name><surname>Cerami</surname><given-names>E.</given-names></name><name><surname>Sander</surname><given-names>C.</given-names></name><name><surname>Schultz</surname><given-names>N.</given-names></name></person-group>
<article-title>Mutual exclusivity analysis identifies oncogenic network modules</article-title>
<source>Genome Res.</source>
<year>2012</year>
<volume>22</volume>
<fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">21908773</pub-id></element-citation></ref><ref id="B100"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>Q.</given-names></name><name><surname>Hou</surname><given-names>J.P.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name></person-group>
<article-title>A network-assisted co-clustering algorithm to discover cancer subtypes based on gene expression</article-title>
<source>BMC Bioinformatics</source>
<year>2014</year>
<volume>15</volume>
<fpage>37</fpage><pub-id pub-id-type="pmid">24491042</pub-id></element-citation></ref><ref id="B101"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engin</surname><given-names>H.B.</given-names></name><name><surname>Guney</surname><given-names>E.</given-names></name><name><surname>Keskin</surname><given-names>O.</given-names></name><name><surname>Oliva</surname><given-names>B.</given-names></name><name><surname>Gursoy</surname><given-names>A.</given-names></name></person-group>
<article-title>Integrating structure to protein-protein interaction networks that drive metastasis to brain and lung in breast cancer</article-title>
<source>PLoS One</source>
<year>2013</year>
<volume>8</volume>
<fpage>e81035</fpage><pub-id pub-id-type="pmid">24278371</pub-id></element-citation></ref><ref id="B102"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gulati</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>T.M.K.</given-names></name><name><surname>Bates</surname><given-names>P.A.</given-names></name></person-group>
<article-title>Cancer networks and beyond: interpreting mutations using the human interactome and protein structure</article-title>
<source>Semin. Cancer Biol.</source>
<year>2013</year>
<volume>23</volume>
<fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">23680723</pub-id></element-citation></ref><ref id="B103"><label>103.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Habchi</surname><given-names>J.</given-names></name><name><surname>Tompa</surname><given-names>P.</given-names></name><name><surname>Longhi</surname><given-names>S.</given-names></name><name><surname>Uversky</surname><given-names>V.N.</given-names></name></person-group>
<article-title>Introducing protein intrinsic disorder</article-title>
<source>Chem. Rev.</source>
<year>2014</year>
<volume>114</volume>
<fpage>6561</fpage><lpage>6588</lpage><pub-id pub-id-type="pmid">24739139</pub-id></element-citation></ref><ref id="B104"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Babu</surname><given-names>M.M.</given-names></name><name><surname>van&#x000a0;der&#x000a0;Lee</surname><given-names>R.</given-names></name><name><surname>de&#x000a0;Groot</surname><given-names>N.S.</given-names></name><name><surname>Gsponer</surname><given-names>J.</given-names></name></person-group>
<article-title>Intrinsically disordered proteins: regulation and disease</article-title>
<source>Curr. Opin. Struct. Biol.</source>
<year>2011</year>
<volume>21</volume>
<fpage>432</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">21514144</pub-id></element-citation></ref><ref id="B105"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mitra</surname><given-names>S.A.</given-names></name><name><surname>Mitra</surname><given-names>A.P.</given-names></name><name><surname>Triche</surname><given-names>T.J.</given-names></name></person-group>
<article-title>A central role for long non-coding RNA in cancer</article-title>
<source>Front. Genet.</source>
<year>2012</year>
<volume>3</volume>
<fpage>17</fpage><pub-id pub-id-type="pmid">22363342</pub-id></element-citation></ref><ref id="B106"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group>
<article-title>Targeting long non-coding RNAs in cancers: progress and prospects</article-title>
<source>Int. J. Biochem. Cell Biol.</source>
<year>2013</year>
<volume>45</volume>
<fpage>1895</fpage><lpage>1910</lpage><pub-id pub-id-type="pmid">23748105</pub-id></element-citation></ref><ref id="B107"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haemmerle</surname><given-names>M.</given-names></name><name><surname>Gutschner</surname><given-names>T.</given-names></name></person-group>
<article-title>Long non-coding RNAs in cancer and development: where do we go from here?</article-title>
<source>Int. J. Mol. Sci.</source>
<year>2015</year>
<volume>16</volume>
<fpage>1395</fpage><lpage>1405</lpage><pub-id pub-id-type="pmid">25580533</pub-id></element-citation></ref><ref id="B108"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prensner</surname><given-names>J.R.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name></person-group>
<article-title>The emergence of lncRNAs in cancer biology</article-title>
<source>Cancer Discov.</source>
<year>2011</year>
<volume>1</volume>
<fpage>391</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">22096659</pub-id></element-citation></ref><ref id="B109"><label>109.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>S.A.</given-names></name><name><surname>Laxman</surname><given-names>B.</given-names></name><name><surname>Dhanasekaran</surname><given-names>S.M.</given-names></name><name><surname>Helgeson</surname><given-names>B.E.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Morris</surname><given-names>D.S.</given-names></name><name><surname>Menon</surname><given-names>A.</given-names></name><name><surname>Jing</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><etal/></person-group>
<article-title>Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer</article-title>
<source>Nature</source>
<year>2007</year>
<volume>448</volume>
<fpage>595</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">17671502</pub-id></element-citation></ref><ref id="B110"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Takahashi</surname><given-names>N.</given-names></name><name><surname>Kakegawa</surname><given-names>E.</given-names></name><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name><name><surname>Kayano</surname><given-names>H.</given-names></name><name><surname>Niitsu</surname><given-names>N.</given-names></name><name><surname>Jinnai</surname><given-names>I.</given-names></name><name><surname>Bessho</surname><given-names>M.</given-names></name></person-group>
<article-title>The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma</article-title>
<source>Cancer Genet. Cytogenet.</source>
<year>2008</year>
<volume>182</volume>
<fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">18406879</pub-id></element-citation></ref><ref id="B111"><label>111.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shahrouki</surname><given-names>P.</given-names></name><name><surname>Larsson</surname><given-names>E.</given-names></name></person-group>
<article-title>The non-coding oncogene: a case of missing DNA evidence?</article-title>
<source>Front. Genet.</source>
<year>2012</year>
<volume>3</volume>
<fpage>170</fpage><pub-id pub-id-type="pmid">22988449</pub-id></element-citation></ref><ref id="B112"><label>112.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ren</surname><given-names>S.</given-names></name><name><surname>Peng</surname><given-names>Z.</given-names></name><name><surname>Mao</surname><given-names>J.-H.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yi</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><etal/></person-group>
<article-title>RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings</article-title>
<source>Cell Res.</source>
<year>2012</year>
<volume>22</volume>
<fpage>806</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">22349460</pub-id></element-citation></ref><ref id="B113"><label>113.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>S.</given-names></name><name><surname>Jing</surname><given-names>T.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome</article-title>
<source>Urol. Oncol. Semin. Orig. Investig.</source>
<year>2015</year>
<volume>33</volume>
<fpage>384.e9</fpage><lpage>384.e20</lpage></element-citation></ref><ref id="B114"><label>114.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>J.</given-names></name><name><surname>An</surname><given-names>J.</given-names></name><name><surname>Seim</surname><given-names>I.</given-names></name><name><surname>Walpole</surname><given-names>C.</given-names></name><name><surname>Hoffman</surname><given-names>A.</given-names></name><name><surname>Moya</surname><given-names>L.</given-names></name><name><surname>Srinivasan</surname><given-names>S.</given-names></name><name><surname>Perry-Keene</surname><given-names>J.L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Lehman</surname><given-names>M.L.</given-names></name><etal/></person-group>
<article-title>Fusion transcript loci share many genomic features with non-fusion loci</article-title>
<source>BMC Genomics</source>
<year>2015</year>
<volume>16</volume>
<fpage>1021</fpage><pub-id pub-id-type="pmid">26626734</pub-id></element-citation></ref><ref id="B115"><label>115.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gingeras</surname><given-names>T.R.</given-names></name></person-group>
<article-title>Implications of chimaeric non-co-linear transcripts</article-title>
<source>Nature</source>
<year>2009</year>
<volume>461</volume>
<fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">19741701</pub-id></element-citation></ref><ref id="B116"><label>116.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Houseley</surname><given-names>J.</given-names></name><name><surname>Tollervey</surname><given-names>D.</given-names></name></person-group>
<article-title>Apparent non-canonical trans-splicing is generated by reverse transcriptase in vitro</article-title>
<source>PLoS One</source>
<year>2010</year>
<volume>5</volume>
<fpage>e12271</fpage><pub-id pub-id-type="pmid">20805885</pub-id></element-citation></ref><ref id="B117"><label>117.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>C.-Y.</given-names></name><name><surname>Liu</surname><given-names>H.-J.</given-names></name><name><surname>Hung</surname><given-names>L.-Y.</given-names></name><name><surname>Kuo</surname><given-names>H.-C.</given-names></name><name><surname>Chuang</surname><given-names>T.-J.</given-names></name></person-group>
<article-title>Is an observed non-co-linear RNA product spliced in trans, in cis or just in vitro?</article-title>
<source>Nucleic Acids Res.</source>
<year>2014</year>
<volume>42</volume>
<fpage>9410</fpage><lpage>9423</lpage><pub-id pub-id-type="pmid">25053845</pub-id></element-citation></ref><ref id="B118"><label>118.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akiva</surname><given-names>P.</given-names></name><name><surname>Toporik</surname><given-names>A.</given-names></name><name><surname>Edelheit</surname><given-names>S.</given-names></name><name><surname>Peretz</surname><given-names>Y.</given-names></name><name><surname>Diber</surname><given-names>A.</given-names></name><name><surname>Shemesh</surname><given-names>R.</given-names></name><name><surname>Novik</surname><given-names>A.</given-names></name><name><surname>Sorek</surname><given-names>R.</given-names></name></person-group>
<article-title>Transcription-mediated gene fusion in the human genome</article-title>
<source>Genome Res.</source>
<year>2006</year>
<volume>16</volume>
<fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16344562</pub-id></element-citation></ref><ref id="B119"><label>119.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parra</surname><given-names>G.</given-names></name><name><surname>Reymond</surname><given-names>A.</given-names></name><name><surname>Dabbouseh</surname><given-names>N.</given-names></name><name><surname>Dermitzakis</surname><given-names>E.T.</given-names></name><name><surname>Castelo</surname><given-names>R.</given-names></name><name><surname>Thomson</surname><given-names>T.M.</given-names></name><name><surname>Antonarakis</surname><given-names>S.E.</given-names></name><name><surname>Guig&#x000f3;</surname><given-names>R.</given-names></name></person-group>
<article-title>Tandem chimerism as a means to increase protein complexity in the human genome</article-title>
<source>Genome Res.</source>
<year>2006</year>
<volume>16</volume>
<fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16344564</pub-id></element-citation></ref><ref id="B120"><label>120.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Denoeud</surname><given-names>F.</given-names></name><name><surname>Kapranov</surname><given-names>P.</given-names></name><name><surname>Ucla</surname><given-names>C.</given-names></name><name><surname>Frankish</surname><given-names>A.</given-names></name><name><surname>Castelo</surname><given-names>R.</given-names></name><name><surname>Drenkow</surname><given-names>J.</given-names></name><name><surname>Lagarde</surname><given-names>J.</given-names></name><name><surname>Alioto</surname><given-names>T.</given-names></name><name><surname>Manzano</surname><given-names>C.</given-names></name><name><surname>Chrast</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Prominent use of distal 5&#x02032; transcription start sites and discovery of a large number of additional exons in ENCODE regions</article-title>
<source>Genome Res.</source>
<year>2007</year>
<volume>17</volume>
<fpage>746</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">17567994</pub-id></element-citation></ref><ref id="B121"><label>121.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Djebali</surname><given-names>S.</given-names></name><name><surname>Lagarde</surname><given-names>J.</given-names></name><name><surname>Kapranov</surname><given-names>P.</given-names></name><name><surname>Lacroix</surname><given-names>V.</given-names></name><name><surname>Borel</surname><given-names>C.</given-names></name><name><surname>Mudge</surname><given-names>J.M.</given-names></name><name><surname>Howald</surname><given-names>C.</given-names></name><name><surname>Foissac</surname><given-names>S.</given-names></name><name><surname>Ucla</surname><given-names>C.</given-names></name><name><surname>Chrast</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Evidence for transcript networks composed of chimeric RNAs in human cells</article-title>
<source>PLoS One</source>
<year>2012</year>
<volume>7</volume>
<fpage>e28213</fpage><pub-id pub-id-type="pmid">22238572</pub-id></element-citation></ref><ref id="B122"><label>122.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Casado-Vela</surname><given-names>J.</given-names></name><name><surname>Lacal</surname><given-names>J.C.</given-names></name><name><surname>Elortza</surname><given-names>F.</given-names></name></person-group>
<article-title>Protein chimerism: novel source of protein diversity in humans adds complexity to bottom-up proteomics</article-title>
<source>Proteomics</source>
<year>2013</year>
<volume>13</volume>
<fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">23161619</pub-id></element-citation></ref><ref id="B123"><label>123.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nome</surname><given-names>T.</given-names></name><name><surname>Hoff</surname><given-names>A.M.</given-names></name><name><surname>Bakken</surname><given-names>A.C.</given-names></name><name><surname>Rognum</surname><given-names>T.O.</given-names></name><name><surname>Nesbakken</surname><given-names>A.</given-names></name><name><surname>Skotheim</surname><given-names>R.I.</given-names></name></person-group>
<article-title>High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants</article-title>
<source>PLoS One</source>
<year>2014</year>
<volume>9</volume>
<fpage>e91264</fpage><pub-id pub-id-type="pmid">24608966</pub-id></element-citation></ref><ref id="B124"><label>124.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Mor</surname><given-names>G.</given-names></name><name><surname>Sklar</surname><given-names>J.</given-names></name></person-group>
<article-title>A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells</article-title>
<source>Science</source>
<year>2008</year>
<volume>321</volume>
<fpage>1357</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">18772439</pub-id></element-citation></ref><ref id="B125"><label>125.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rickman</surname><given-names>D.S.</given-names></name><name><surname>Pflueger</surname><given-names>D.</given-names></name><name><surname>Moss</surname><given-names>B.</given-names></name><name><surname>VanDoren</surname><given-names>V.E.</given-names></name><name><surname>Chen</surname><given-names>C.X.</given-names></name><name><surname>de&#x000a0;la&#x000a0;Taille</surname><given-names>A.</given-names></name><name><surname>Kuefer</surname><given-names>R.</given-names></name><name><surname>Tewari</surname><given-names>A.K.</given-names></name><name><surname>Setlur</surname><given-names>S.R.</given-names></name><name><surname>Demichelis</surname><given-names>F.</given-names></name><etal/></person-group>
<article-title>SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer</article-title>
<source>Cancer Res.</source>
<year>2009</year>
<volume>69</volume>
<fpage>2734</fpage><lpage>2738</lpage><pub-id pub-id-type="pmid">19293179</pub-id></element-citation></ref><ref id="B126"><label>126.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Albertson</surname><given-names>D.G.</given-names></name><name><surname>Collins</surname><given-names>C.</given-names></name><name><surname>McCormick</surname><given-names>F.</given-names></name><name><surname>Gray</surname><given-names>J.W.</given-names></name></person-group>
<article-title>Chromosome aberrations in solid tumors</article-title>
<source>Nat. Genet.</source>
<year>2003</year>
<volume>34</volume>
<fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">12923544</pub-id></element-citation></ref><ref id="B127"><label>127.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name></person-group>
<article-title>Identification of cancer gene fusions based on advanced analysis of the human genome or transcriptome</article-title>
<source>Front. Med.</source>
<year>2013</year>
<volume>7</volume>
<fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">23807217</pub-id></element-citation></ref><ref id="B128"><label>128.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Campbell</surname><given-names>P.J.</given-names></name><name><surname>Stephens</surname><given-names>P.J.</given-names></name><name><surname>Pleasance</surname><given-names>E.D.</given-names></name><name><surname>O'Meara</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Santarius</surname><given-names>T.</given-names></name><name><surname>Stebbings</surname><given-names>L.A.</given-names></name><name><surname>Leroy</surname><given-names>C.</given-names></name><name><surname>Edkins</surname><given-names>S.</given-names></name><name><surname>Hardy</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing</article-title>
<source>Nat. Genet.</source>
<year>2008</year>
<volume>40</volume>
<fpage>722</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">18438408</pub-id></element-citation></ref><ref id="B129"><label>129.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maher</surname><given-names>C.A.</given-names></name><name><surname>Kumar-Sinha</surname><given-names>C.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Jing</surname><given-names>X.</given-names></name><name><surname>Sam</surname><given-names>L.</given-names></name><name><surname>Barrette</surname><given-names>T.</given-names></name><name><surname>Palanisamy</surname><given-names>N.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Transcriptome sequencing to detect gene fusions in cancer</article-title>
<source>Nature</source>
<year>2009</year>
<volume>458</volume>
<fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">19136943</pub-id></element-citation></ref><ref id="B130"><label>130.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>P.</given-names></name><name><surname>Pao</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name></person-group>
<article-title>Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives</article-title>
<source>Brief. Bioinform.</source>
<year>2013</year>
<volume>14</volume>
<fpage>506</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">22877769</pub-id></element-citation></ref><ref id="B131"><label>131.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sboner</surname><given-names>A.</given-names></name><name><surname>Habegger</surname><given-names>L.</given-names></name><name><surname>Pflueger</surname><given-names>D.</given-names></name><name><surname>Terry</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>D.Z.</given-names></name><name><surname>Rozowsky</surname><given-names>J.S.</given-names></name><name><surname>Tewari</surname><given-names>A.K.</given-names></name><name><surname>Kitabayashi</surname><given-names>N.</given-names></name><name><surname>Moss</surname><given-names>B.J.</given-names></name><name><surname>Chee</surname><given-names>M.S.</given-names></name><etal/></person-group>
<article-title>FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data</article-title>
<source>Genome Biol.</source>
<year>2010</year>
<volume>11</volume>
<fpage>R104</fpage><pub-id pub-id-type="pmid">20964841</pub-id></element-citation></ref><ref id="B132"><label>132.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weirather</surname><given-names>J.L.</given-names></name><name><surname>Afshar</surname><given-names>P.T.</given-names></name><name><surname>Clark</surname><given-names>T.A.</given-names></name><name><surname>Tseng</surname><given-names>E.</given-names></name><name><surname>Powers</surname><given-names>L.S.</given-names></name><name><surname>Underwood</surname><given-names>J.G.</given-names></name><name><surname>Zabner</surname><given-names>J.</given-names></name><name><surname>Korlach</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>W.H.</given-names></name><name><surname>Au</surname><given-names>K.F.</given-names></name></person-group>
<article-title>Characterization of fusion genes and the significantly expressed fusion isoforms in breast cancer by hybrid sequencing</article-title>
<source>Nucleic Acids Res.</source>
<year>2015</year>
<volume>43</volume>
<fpage>e116</fpage><pub-id pub-id-type="pmid">26040699</pub-id></element-citation></ref><ref id="B133"><label>133.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidson</surname><given-names>N.M.</given-names></name><name><surname>Majewski</surname><given-names>I.J.</given-names></name><name><surname>Oshlack</surname><given-names>A.</given-names></name></person-group>
<article-title>JAFFA: High sensitivity transcriptome-focused fusion gene detection</article-title>
<source>Genome Med.</source>
<year>2015</year>
<volume>7</volume>
<fpage>43</fpage><pub-id pub-id-type="pmid">26019724</pub-id></element-citation></ref><ref id="B134"><label>134.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez-Cuesta</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>R.</given-names></name><name><surname>Menon</surname><given-names>R.</given-names></name><name><surname>George</surname><given-names>J.</given-names></name><name><surname>Lorenz</surname><given-names>S.</given-names></name><name><surname>Meza-Zepeda</surname><given-names>L.A.</given-names></name><name><surname>Peifer</surname><given-names>M.</given-names></name><name><surname>Plenker</surname><given-names>D.</given-names></name><name><surname>Heuckmann</surname><given-names>J.M.</given-names></name><name><surname>Leenders</surname><given-names>F.</given-names></name><etal/></person-group>
<article-title>Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data</article-title>
<source>Genome Biol.</source>
<year>2015</year>
<volume>16</volume>
<fpage>7</fpage><pub-id pub-id-type="pmid">25650807</pub-id></element-citation></ref><ref id="B135"><label>135.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qadir</surname><given-names>M. a</given-names></name><name><surname>Zhan</surname><given-names>S.H.</given-names></name><name><surname>Kwok</surname><given-names>B.</given-names></name><name><surname>Bruestle</surname><given-names>J.</given-names></name><name><surname>Drees</surname><given-names>B.</given-names></name><name><surname>Popescu</surname><given-names>O.E.</given-names></name><name><surname>Sorensen</surname><given-names>P.H.</given-names></name></person-group>
<article-title>ChildSeq-RNA: A next-generation sequencing-based diagnostic assay to identify known fusion transcripts in childhood sarcomas</article-title>
<source>J. Mol. Diagnostics</source>
<year>2014</year>
<volume>16</volume>
<fpage>361</fpage><lpage>370</lpage></element-citation></ref><ref id="B136"><label>136.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torres-Garc&#x000ed;a</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Sivachenko</surname><given-names>A.</given-names></name><name><surname>Vegesna</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yao</surname><given-names>R.</given-names></name><name><surname>Berger</surname><given-names>M.F.</given-names></name><name><surname>Weinstein</surname><given-names>J.N.</given-names></name><name><surname>Getz</surname><given-names>G.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.W.</given-names></name></person-group>
<article-title>PRADA: pipeline for RNA sequencing data analysis</article-title>
<source>Bioinformatics</source>
<year>2014</year>
<volume>30</volume>
<fpage>2224</fpage><lpage>2226</lpage><pub-id pub-id-type="pmid">24695405</pub-id></element-citation></ref><ref id="B137"><label>137.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chu</surname><given-names>H.-T.</given-names></name><name><surname>Hsiao</surname><given-names>W.W.L.</given-names></name><name><surname>Chen</surname><given-names>J.-C.</given-names></name><name><surname>Yeh</surname><given-names>T.-J.</given-names></name><name><surname>Tsai</surname><given-names>M.-H.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.-W.</given-names></name><name><surname>Lee</surname><given-names>S.-A.</given-names></name><name><surname>Chen</surname><given-names>C.-C.</given-names></name><name><surname>Tsao</surname><given-names>T.T.H.</given-names></name><etal/></person-group>
<article-title>EBARDenovo: highly accurate de novo assembly of RNA-Seq with efficient chimera-detection</article-title>
<source>Bioinformatics</source>
<year>2013</year>
<volume>29</volume>
<fpage>1004</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">23457040</pub-id></element-citation></ref><ref id="B138"><label>138.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>C.J.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name></person-group>
<article-title>FusionQ: a novel approach for gene fusion detection and quantification from paired-end RNA-Seq</article-title>
<source>BMC Bioinformatics</source>
<year>2013</year>
<volume>14</volume>
<fpage>193</fpage><pub-id pub-id-type="pmid">23768108</pub-id></element-citation></ref><ref id="B139"><label>139.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hiltemann</surname><given-names>S.</given-names></name><name><surname>McClellan</surname><given-names>E. A.</given-names></name><name><surname>Van&#x000a0;Nijnatten</surname><given-names>J.</given-names></name><name><surname>Horsman</surname><given-names>S.</given-names></name><name><surname>Palli</surname><given-names>I.</given-names></name><name><surname>Alves</surname><given-names>I.T.</given-names></name><name><surname>Hartjes</surname><given-names>T.</given-names></name><name><surname>Trapman</surname><given-names>J.</given-names></name><name><surname>Van&#x000a0;Der&#x000a0;Spek</surname><given-names>P.</given-names></name><name><surname>Jenster</surname><given-names>G.</given-names></name><etal/></person-group>
<article-title>iFUSE: integrated fusion gene explorer</article-title>
<source>Bioinformatics</source>
<year>2013</year>
<volume>29</volume>
<fpage>1700</fpage><lpage>1701</lpage><pub-id pub-id-type="pmid">23661695</pub-id></element-citation></ref><ref id="B140"><label>140.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Qiu</surname><given-names>K.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>P.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Nickerson</surname><given-names>M.L.</given-names></name><name><surname>Wan</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data</article-title>
<source>Genome Biol.</source>
<year>2013</year>
<volume>14</volume>
<fpage>R12</fpage><pub-id pub-id-type="pmid">23409703</pub-id></element-citation></ref><ref id="B141"><label>141.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Lam</surname><given-names>T.W.</given-names></name><name><surname>Peng</surname><given-names>Z.</given-names></name><name><surname>Yiu</surname><given-names>S.M.</given-names></name></person-group>
<article-title>SOAPfusion: A robust and effective computational fusion discovery tool for RNA-seq reads</article-title>
<source>Bioinformatics</source>
<year>2013</year>
<volume>29</volume>
<fpage>2971</fpage><lpage>2978</lpage><pub-id pub-id-type="pmid">24123671</pub-id></element-citation></ref><ref id="B142"><label>142.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abate</surname><given-names>F.</given-names></name><name><surname>Acquaviva</surname><given-names>A.</given-names></name><name><surname>Paciello</surname><given-names>G.</given-names></name><name><surname>Foti</surname><given-names>C.</given-names></name><name><surname>Ficarra</surname><given-names>E.</given-names></name><name><surname>Ferrarini</surname><given-names>A.</given-names></name><name><surname>Delledonne</surname><given-names>M.</given-names></name><name><surname>Iacobucci</surname><given-names>I.</given-names></name><name><surname>Soverini</surname><given-names>S.</given-names></name><name><surname>Martinelli</surname><given-names>G.</given-names></name><etal/></person-group>
<article-title>Bellerophontes: An RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model</article-title>
<source>Bioinformatics</source>
<year>2012</year>
<volume>28</volume>
<fpage>2114</fpage><lpage>2121</lpage><pub-id pub-id-type="pmid">22711792</pub-id></element-citation></ref><ref id="B143"><label>143.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Wallis</surname><given-names>J.W.</given-names></name><name><surname>Kandoth</surname><given-names>C.</given-names></name><name><surname>Kalicki-Veizer</surname><given-names>J.M.</given-names></name><name><surname>Mungall</surname><given-names>K.L.</given-names></name><name><surname>Mungall</surname><given-names>A.J.</given-names></name><name><surname>Jones</surname><given-names>S.J.</given-names></name><name><surname>Marra</surname><given-names>M.A.</given-names></name><name><surname>Ley</surname><given-names>T.J.</given-names></name><name><surname>Mardis</surname><given-names>E.R.</given-names></name><etal/></person-group>
<article-title>BreakFusion: targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data</article-title>
<source>Bioinformatics</source>
<year>2012</year>
<volume>28</volume>
<fpage>1923</fpage><lpage>1924</lpage><pub-id pub-id-type="pmid">22563071</pub-id></element-citation></ref><ref id="B144"><label>144.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Supper</surname><given-names>J.</given-names></name><name><surname>Gugenmus</surname><given-names>C.</given-names></name><name><surname>Wollnik</surname><given-names>J.</given-names></name><name><surname>Drueke</surname><given-names>T.</given-names></name><name><surname>Scherf</surname><given-names>M.</given-names></name><name><surname>Hahn</surname><given-names>A.</given-names></name><name><surname>Grote</surname><given-names>K.</given-names></name><name><surname>Bretschneider</surname><given-names>N.</given-names></name><name><surname>Klocke</surname><given-names>B.</given-names></name><name><surname>Zinser</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>Detecting and visualizing gene fusions</article-title>
<source>Methods</source>
<year>2013</year>
<volume>59</volume>
<fpage>187</fpage><lpage>191</lpage></element-citation></ref><ref id="B145"><label>145.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benelli</surname><given-names>M.</given-names></name><name><surname>Pescucci</surname><given-names>C.</given-names></name><name><surname>Marseglia</surname><given-names>G.</given-names></name><name><surname>Severgnini</surname><given-names>M.</given-names></name><name><surname>Torricelli</surname><given-names>F.</given-names></name><name><surname>Magi</surname><given-names>A.</given-names></name></person-group>
<article-title>Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript</article-title>
<source>Bioinformatics</source>
<year>2012</year>
<volume>28</volume>
<fpage>3232</fpage><lpage>3239</lpage><pub-id pub-id-type="pmid">23093608</pub-id></element-citation></ref><ref id="B146"><label>146.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Piazza</surname><given-names>R.</given-names></name><name><surname>Pirola</surname><given-names>A.</given-names></name><name><surname>Spinelli</surname><given-names>R.</given-names></name><name><surname>Valletta</surname><given-names>S.</given-names></name><name><surname>Redaelli</surname><given-names>S.</given-names></name><name><surname>Magistroni</surname><given-names>V.</given-names></name><name><surname>Gambacorti-Passerini</surname><given-names>C.</given-names></name></person-group>
<article-title>FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery</article-title>
<source>Nucleic Acids Res.</source>
<year>2012</year>
<volume>40</volume>
<fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21908400</pub-id></element-citation></ref><ref id="B147"><label>147.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Francis</surname><given-names>R.W.</given-names></name><name><surname>Thompson-Wicking</surname><given-names>K.</given-names></name><name><surname>Carter</surname><given-names>K.W.</given-names></name><name><surname>Anderson</surname><given-names>D.</given-names></name><name><surname>Kees</surname><given-names>U.R.</given-names></name><name><surname>Beesley</surname><given-names>A.H.</given-names></name></person-group>
<article-title>Fusionfinder: a software tool to identify expressed gene fusion candidates from RNA-seq data</article-title>
<source>PLoS One</source>
<year>2012</year>
<volume>7</volume>
<fpage>e39987</fpage><pub-id pub-id-type="pmid">22761941</pub-id></element-citation></ref><ref id="B148"><label>148.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakarya</surname><given-names>O.</given-names></name><name><surname>Breu</surname><given-names>H.</given-names></name><name><surname>Radovich</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.N.</given-names></name><name><surname>Barbacioru</surname><given-names>C.</given-names></name><name><surname>Utiramerur</surname><given-names>S.</given-names></name><name><surname>Whitley</surname><given-names>P.P.</given-names></name><name><surname>Brockman</surname><given-names>J.P.</given-names></name><name><surname>Vatta</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>RNA-Seq mapping and detection of gene fusions with a suffix array algorithm</article-title>
<source>PLoS Comput. Biol.</source>
<year>2012</year>
<volume>8</volume>
<fpage>e1002464</fpage><pub-id pub-id-type="pmid">22496636</pub-id></element-citation></ref><ref id="B149"><label>149.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McPherson</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Wyatt</surname><given-names>A.W.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Collins</surname><given-names>C.</given-names></name><name><surname>Sahinalp</surname><given-names>S.C.</given-names></name></person-group>
<article-title>nFuse: discovery of complex genomic rearrangements in cancer using high-throughput sequencing</article-title>
<source>Genome Res.</source>
<year>2012</year>
<volume>22</volume>
<fpage>2250</fpage><lpage>2261</lpage><pub-id pub-id-type="pmid">22745232</pub-id></element-citation></ref><ref id="B150"><label>150.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iyer</surname><given-names>M.K.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name><name><surname>Maher</surname><given-names>C. A.</given-names></name></person-group>
<article-title>ChimeraScan: a tool for identifying chimeric transcription in sequencing data</article-title>
<source>Bioinformatics</source>
<year>2011</year>
<volume>27</volume>
<fpage>2903</fpage><lpage>2904</lpage><pub-id pub-id-type="pmid">21840877</pub-id></element-citation></ref><ref id="B151"><label>151.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McPherson</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Hajirasouliha</surname><given-names>I.</given-names></name><name><surname>Hormozdiari</surname><given-names>F.</given-names></name><name><surname>Hach</surname><given-names>F.</given-names></name><name><surname>Lapuk</surname><given-names>A.</given-names></name><name><surname>Volik</surname><given-names>S.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Collins</surname><given-names>C.</given-names></name><name><surname>Sahinalp</surname><given-names>S.C.</given-names></name></person-group>
<article-title>Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data</article-title>
<source>Bioinformatics</source>
<year>2011</year>
<volume>27</volume>
<fpage>1481</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">21478487</pub-id></element-citation></ref><ref id="B152"><label>152.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McPherson</surname><given-names>A.</given-names></name><name><surname>Hormozdiari</surname><given-names>F.</given-names></name><name><surname>Zayed</surname><given-names>A.</given-names></name><name><surname>Giuliany</surname><given-names>R.</given-names></name><name><surname>Ha</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>M.G.F.</given-names></name><name><surname>Griffith</surname><given-names>M.</given-names></name><name><surname>Moussavi</surname><given-names>A.</given-names></name><name><surname>Senz</surname><given-names>J.</given-names></name><name><surname>Melnyk</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>Defuse: an algorithm for gene fusion discovery in tumor rna-seq data</article-title>
<source>PLoS Comput. Biol.</source>
<year>2011</year>
<volume>7</volume>
<fpage>e1001138</fpage><pub-id pub-id-type="pmid">21625565</pub-id></element-citation></ref><ref id="B153"><label>153.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chien</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>D.I.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name></person-group>
<article-title>FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq</article-title>
<source>Bioinformatics</source>
<year>2011</year>
<volume>27</volume>
<fpage>1708</fpage><lpage>1710</lpage><pub-id pub-id-type="pmid">21546395</pub-id></element-citation></ref><ref id="B154"><label>154.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ge</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Juan</surname><given-names>T.</given-names></name><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Newman</surname><given-names>M.</given-names></name><name><surname>Hoeck</surname><given-names>W.</given-names></name></person-group>
<article-title>FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution</article-title>
<source>Bioinformatics</source>
<year>2011</year>
<volume>27</volume>
<fpage>1922</fpage><lpage>1928</lpage><pub-id pub-id-type="pmid">21593131</pub-id></element-citation></ref><ref id="B155"><label>155.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kinsella</surname><given-names>M.</given-names></name><name><surname>Harismendy</surname><given-names>O.</given-names></name><name><surname>Nakano</surname><given-names>M.</given-names></name><name><surname>Frazer</surname><given-names>K.A.</given-names></name><name><surname>Bafna</surname><given-names>V.</given-names></name></person-group>
<article-title>Sensitive gene fusion detection using ambiguously mapping RNA-Seq read pairs</article-title>
<source>Bioinformatics</source>
<year>2011</year>
<volume>27</volume>
<fpage>1068</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">21330288</pub-id></element-citation></ref><ref id="B156"><label>156.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asmann</surname><given-names>Y.W.</given-names></name><name><surname>Hossain</surname><given-names>A.</given-names></name><name><surname>Necela</surname><given-names>B.M.</given-names></name><name><surname>Middha</surname><given-names>S.</given-names></name><name><surname>Kalari</surname><given-names>K.R.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Chai</surname><given-names>H.-S.</given-names></name><name><surname>Williamson</surname><given-names>D.W.</given-names></name><name><surname>Radisky</surname><given-names>D.</given-names></name><name><surname>Schroth</surname><given-names>G.P.</given-names></name><etal/></person-group>
<article-title>A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines</article-title>
<source>Nucleic Acids Res.</source>
<year>2011</year>
<volume>39</volume>
<fpage>e100</fpage><pub-id pub-id-type="pmid">21622959</pub-id></element-citation></ref><ref id="B157"><label>157.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Salzberg</surname><given-names>S.L.</given-names></name></person-group>
<article-title>TopHat-Fusion: an algorithm for discovery of novel fusion transcripts</article-title>
<source>Genome Biol</source>
<year>2011</year>
<volume>12</volume>
<fpage>R72</fpage><pub-id pub-id-type="pmid">21835007</pub-id></element-citation></ref><ref id="B158"><label>158.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>White</surname><given-names>N.M.</given-names></name><name><surname>Schmidt</surname><given-names>H.K.</given-names></name><name><surname>Fulton</surname><given-names>R.S.</given-names></name><name><surname>Tomlinson</surname><given-names>C.</given-names></name><name><surname>Warren</surname><given-names>W.C.</given-names></name><name><surname>Wilson</surname><given-names>R.K.</given-names></name><name><surname>Maher</surname><given-names>C.A.</given-names></name></person-group>
<article-title>INTEGRATE: gene fusion discovery using whole genome and transcriptome data</article-title>
<source>Genome Res.</source>
<year>2016</year>
<volume>26</volume>
<fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">26556708</pub-id></element-citation></ref><ref id="B159"><label>159.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Wallis</surname><given-names>J.W.</given-names></name><name><surname>McLellan</surname><given-names>M.D.</given-names></name><name><surname>Larson</surname><given-names>D.E.</given-names></name><name><surname>Kalicki</surname><given-names>J.M.</given-names></name><name><surname>Pohl</surname><given-names>C.S.</given-names></name><name><surname>McGrath</surname><given-names>S.D.</given-names></name><name><surname>Wendl</surname><given-names>M.C.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Locke</surname><given-names>D.P.</given-names></name><etal/></person-group>
<article-title>BreakDancer: an algorithm for high-resolution mapping of genomic structural variation</article-title>
<source>Nat. Methods</source>
<year>2009</year>
<volume>6</volume>
<fpage>677</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">19668202</pub-id></element-citation></ref><ref id="B160"><label>160.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Mullighan</surname><given-names>C.G.</given-names></name><name><surname>Easton</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>S.</given-names></name><name><surname>Heatley</surname><given-names>S.L.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Rusch</surname><given-names>M.C.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Harris</surname><given-names>C.C.</given-names></name><name><surname>Ding</surname><given-names>L.</given-names></name><etal/></person-group>
<article-title>CREST maps somatic structural variation in cancer genomes with base-pair resolution</article-title>
<source>Nat. Methods</source>
<year>2011</year>
<volume>8</volume>
<fpage>652</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">21666668</pub-id></element-citation></ref><ref id="B161"><label>161.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Tsai</surname><given-names>W.-H.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Huo</surname><given-names>Z.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>T.</given-names></name><name><surname>Chang</surname><given-names>T.-Y.</given-names></name><name><surname>Priedigkeit</surname><given-names>N.M.</given-names></name><etal/></person-group>
<article-title>Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data</article-title>
<source>Nucleic Acids Res.</source>
<year>2015</year><comment>doi:10.1093/nar/gkv1234</comment></element-citation></ref><ref id="B162"><label>162.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beccuti</surname><given-names>M.</given-names></name><name><surname>Carrara</surname><given-names>M.</given-names></name><name><surname>Cordero</surname><given-names>F.</given-names></name><name><surname>Lazzarato</surname><given-names>F.</given-names></name><name><surname>Donatelli</surname><given-names>S.</given-names></name><name><surname>Nadalin</surname><given-names>F.</given-names></name><name><surname>Policriti</surname><given-names>A.</given-names></name><name><surname>Calogero</surname><given-names>R.A.</given-names></name></person-group>
<article-title>Chimera: a Bioconductor package for secondary analysis of fusion products</article-title>
<source>Bioinformatics</source>
<year>2014</year>
<volume>30</volume>
<fpage>3556</fpage><lpage>3557</lpage><pub-id pub-id-type="pmid">25286921</pub-id></element-citation></ref><ref id="B163"><label>163.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carrara</surname><given-names>M.</given-names></name><name><surname>Beccuti</surname><given-names>M.</given-names></name><name><surname>Lazzarato</surname><given-names>F.</given-names></name><name><surname>Cavallo</surname><given-names>F.</given-names></name><name><surname>Cordero</surname><given-names>F.</given-names></name><name><surname>Donatelli</surname><given-names>S.</given-names></name><name><surname>Calogero</surname><given-names>R.A.</given-names></name></person-group>
<article-title>State-of-the-art fusion-finder algorithms sensitivity and specificity</article-title>
<source>Biomed Res. Int.</source>
<year>2013</year><fpage>340620</fpage><pub-id pub-id-type="pmid">23555082</pub-id></element-citation></ref><ref id="B164"><label>164.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carrara</surname><given-names>M.</given-names></name><name><surname>Beccuti</surname><given-names>M.</given-names></name><name><surname>Cavallo</surname><given-names>F.</given-names></name><name><surname>Donatelli</surname><given-names>S.</given-names></name><name><surname>Lazzarato</surname><given-names>F.</given-names></name><name><surname>Cordero</surname><given-names>F.</given-names></name><name><surname>Calogero</surname><given-names>R. a</given-names></name></person-group>
<article-title>State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?</article-title>
<source>BMC Bioinformatics</source>
<year>2013</year>
<volume>14</volume><issue>Suppl. 7</issue><fpage>S2</fpage><pub-id pub-id-type="pmid">23815381</pub-id></element-citation></ref><ref id="B165"><label>165.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tembe</surname><given-names>W.D.</given-names></name><name><surname>Pond</surname><given-names>S.J.</given-names></name><name><surname>Legendre</surname><given-names>C.</given-names></name><name><surname>Chuang</surname><given-names>H.-Y.</given-names></name><name><surname>Liang</surname><given-names>W.S.</given-names></name><name><surname>Kim</surname><given-names>N.E.</given-names></name><name><surname>Montel</surname><given-names>V.</given-names></name><name><surname>Wong</surname><given-names>S.</given-names></name><name><surname>McDaniel</surname><given-names>T.K.</given-names></name><name><surname>Craig</surname><given-names>D.W.</given-names></name><etal/></person-group>
<article-title>Open-access synthetic spike-in mRNA-seq data for cancer gene fusions</article-title>
<source>BMC Genomics</source>
<year>2014</year>
<volume>15</volume>
<fpage>824</fpage><pub-id pub-id-type="pmid">25266161</pub-id></element-citation></ref><ref id="B166"><label>166.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beccuti</surname><given-names>M.</given-names></name><name><surname>Carrara</surname><given-names>M.</given-names></name><name><surname>Cordero</surname><given-names>F.</given-names></name><name><surname>Donatelli</surname><given-names>S.</given-names></name><name><surname>Calogero</surname><given-names>R.</given-names></name></person-group>
<article-title>The structure of state-of-art gene fusion-finder algorithms</article-title>
<source>OA Bioinforma.</source>
<year>2013</year>
<volume>1</volume>
<fpage>2</fpage></element-citation></ref><ref id="B167"><label>167.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Dietterich</surname><given-names>T.G.</given-names></name></person-group>
<source>Ensemble methods in machine learning</source>
<year>2000</year>
<publisher-loc>Springer-Verlag</publisher-loc><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="B168"><label>168.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Dong</surname><given-names>D.</given-names></name></person-group>
<article-title>FusionCancer: a database of cancer fusion genes derived from RNA-seq data</article-title>
<source>Diagn. Pathol.</source>
<year>2015</year>
<volume>10</volume>
<fpage>131</fpage><pub-id pub-id-type="pmid">26215638</pub-id></element-citation></ref><ref id="B169"><label>169.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.S.</given-names></name><name><surname>Yu</surname><given-names>C.Y.</given-names></name><name><surname>Chuang</surname><given-names>C.Y.</given-names></name><name><surname>Hsiao</surname><given-names>M.</given-names></name><name><surname>Kao</surname><given-names>C.F.</given-names></name><name><surname>Kuo</surname><given-names>H.C.</given-names></name><name><surname>Chuang</surname><given-names>T.J.</given-names></name></person-group>
<article-title>Integrative transcriptome sequencing identifies trans-splicing events with important roles in human embryonic stem cell pluripotency</article-title>
<source>Genome Res</source>
<year>2014</year>
<volume>24</volume>
<fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">24131564</pub-id></element-citation></ref><ref id="B170"><label>170.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.-C.</given-names></name><name><surname>Kannan</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Yen</surname><given-names>L.</given-names></name><name><surname>Milosavljevic</surname><given-names>A.</given-names></name></person-group>
<article-title>Identification of cancer fusion drivers using network fusion centrality</article-title>
<source>Bioinformatics</source>
<year>2013</year>
<volume>29</volume>
<fpage>1174</fpage><lpage>1181</lpage><pub-id pub-id-type="pmid">23505294</pub-id></element-citation></ref><ref id="B171"><label>171.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>N.</given-names></name><name><surname>Kim</surname><given-names>P.</given-names></name><name><surname>Nam</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name></person-group>
<article-title>ChimerDB&#x02013;a knowledgebase for fusion sequences</article-title>
<source>Nucleic Acids Res</source>
<year>2006</year>
<volume>34</volume>
<fpage>D21</fpage><lpage>D24</lpage><pub-id pub-id-type="pmid">16381848</pub-id></element-citation></ref><ref id="B172"><label>172.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huret</surname><given-names>J.L.</given-names></name><name><surname>Dessen</surname><given-names>P.</given-names></name><name><surname>Le&#x000a0;Minor</surname><given-names>S.</given-names></name><name><surname>Bernheim</surname><given-names>A.</given-names></name></person-group>
<article-title>The &#x02018;Atlas of Genetics and Cytogenetics in Oncology and Haematology&#x02019; on the internet and a review on infant leukemias</article-title>
<source>Cancer Genet. Cytogenet.</source>
<year>2000</year>
<volume>120</volume>
<fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">10942808</pub-id></element-citation></ref><ref id="B173"><label>173.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>J.R.</given-names></name><name><surname>Ziman</surname><given-names>R.</given-names></name><name><surname>Yuen</surname><given-names>R.K.C.</given-names></name><name><surname>Feuk</surname><given-names>L.</given-names></name><name><surname>Scherer</surname><given-names>S.W.</given-names></name></person-group>
<article-title>The Database of Genomic Variants: a curated collection of structural variation in the human genome</article-title>
<source>Nucleic Acids Res</source>
<year>2014</year>
<volume>42</volume>
<fpage>D986</fpage><lpage>D992</lpage><pub-id pub-id-type="pmid">24174537</pub-id></element-citation></ref><ref id="B174"><label>174.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Firth</surname><given-names>H. V</given-names></name><name><surname>Richards</surname><given-names>S.M.</given-names></name><name><surname>Bevan</surname><given-names>A.P.</given-names></name><name><surname>Clayton</surname><given-names>S.</given-names></name><name><surname>Corpas</surname><given-names>M.</given-names></name><name><surname>Rajan</surname><given-names>D.</given-names></name><name><surname>Van&#x000a0;Vooren</surname><given-names>S.</given-names></name><name><surname>Moreau</surname><given-names>Y.</given-names></name><name><surname>Pettett</surname><given-names>R.M.</given-names></name><name><surname>Carter</surname><given-names>N.P.</given-names></name></person-group>
<article-title>DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources</article-title>
<source>Am. J. Hum. Genet.</source>
<year>2009</year>
<volume>84</volume>
<fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">19344873</pub-id></element-citation></ref><ref id="B175"><label>175.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bamford</surname><given-names>S.</given-names></name><name><surname>Dawson</surname><given-names>E.</given-names></name><name><surname>Forbes</surname><given-names>S.</given-names></name><name><surname>Clements</surname><given-names>J.</given-names></name><name><surname>Pettett</surname><given-names>R.</given-names></name><name><surname>Dogan</surname><given-names>A.</given-names></name><name><surname>Flanagan</surname><given-names>A.</given-names></name><name><surname>Teague</surname><given-names>J.</given-names></name><name><surname>Futreal</surname><given-names>P.A.</given-names></name><name><surname>Stratton</surname><given-names>M.R.</given-names></name><etal/></person-group>
<article-title>The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website</article-title>
<source>Br. J. Cancer</source>
<year>2004</year>
<volume>91</volume>
<fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">15188009</pub-id></element-citation></ref><ref id="B176"><label>176.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>P.</given-names></name><name><surname>Yoon</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Ko</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name></person-group>
<article-title>ChimerDB 2.0&#x02013;a knowledgebase for fusion genes updated</article-title>
<source>Nucleic Acids Res.</source>
<year>2010</year>
<volume>38</volume>
<fpage>D81</fpage><lpage>D85</lpage><pub-id pub-id-type="pmid">19906715</pub-id></element-citation></ref><ref id="B177"><label>177.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Novo</surname><given-names>F.J.</given-names></name><name><surname>de&#x000a0;Mend&#x000ed;bil</surname><given-names>I.O.</given-names></name><name><surname>Vizmanos</surname><given-names>J.L.</given-names></name></person-group>
<article-title>TICdb: a collection of gene-mapped translocation breakpoints in cancer</article-title>
<source>BMC Genomics</source>
<year>2007</year>
<volume>8</volume>
<fpage>33</fpage><pub-id pub-id-type="pmid">17257420</pub-id></element-citation></ref><ref id="B178"><label>178.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.-S.</given-names></name><name><surname>Huh</surname><given-names>J.-W.</given-names></name><name><surname>Kim</surname><given-names>H.-S.</given-names></name></person-group>
<article-title>HYBRIDdb: a database of hybrid genes in the human genome</article-title>
<source>BMC Genomics</source>
<year>2007</year>
<volume>8</volume>
<fpage>128</fpage><pub-id pub-id-type="pmid">17519042</pub-id></element-citation></ref><ref id="B179"><label>179.</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>F.</given-names></name><name><surname>Johansson</surname><given-names>B.</given-names></name><name><surname>Mertens</surname><given-names>F.</given-names></name></person-group>
<article-title>Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer</article-title><year>2016</year></element-citation></ref><ref id="B180"><label>180.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Forbes</surname><given-names>S.A.</given-names></name><name><surname>Beare</surname><given-names>D.</given-names></name><name><surname>Gunasekaran</surname><given-names>P.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name><name><surname>Bindal</surname><given-names>N.</given-names></name><name><surname>Boutselakis</surname><given-names>H.</given-names></name><name><surname>Ding</surname><given-names>M.</given-names></name><name><surname>Bamford</surname><given-names>S.</given-names></name><name><surname>Cole</surname><given-names>C.</given-names></name><name><surname>Ward</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>COSMIC: exploring the world's knowledge of somatic mutations in human cancer</article-title>
<source>Nucleic Acids Res.</source>
<year>2015</year>
<volume>43</volume>
<fpage>D805</fpage><lpage>D811</lpage><pub-id pub-id-type="pmid">25355519</pub-id></element-citation></ref><ref id="B181"><label>181.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prakash</surname><given-names>T.</given-names></name><name><surname>Sharma</surname><given-names>V.K.</given-names></name><name><surname>Adati</surname><given-names>N.</given-names></name><name><surname>Ozawa</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Nishida</surname><given-names>Y.</given-names></name><name><surname>Fujikake</surname><given-names>T.</given-names></name><name><surname>Takeda</surname><given-names>T.</given-names></name><name><surname>Taylor</surname><given-names>T.D.</given-names></name></person-group>
<article-title>Expression of conjoined genes: another mechanism for gene regulation in eukaryotes</article-title>
<source>PLoS One</source>
<year>2010</year>
<volume>5</volume>
<fpage>e13284</fpage><pub-id pub-id-type="pmid">20967262</pub-id></element-citation></ref><ref id="B182"><label>182.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kong</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Fu</surname><given-names>S.</given-names></name><name><surname>Yuan</surname><given-names>L.-L.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name></person-group>
<article-title>dbCRID: a database of chromosomal rearrangements in human diseases</article-title>
<source>Nucleic Acids Res.</source>
<year>2011</year>
<volume>39</volume>
<fpage>D895</fpage><lpage>D900</lpage><pub-id pub-id-type="pmid">21051346</pub-id></element-citation></ref><ref id="B183"><label>183.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frenkel-Morgenstern</surname><given-names>M.</given-names></name><name><surname>Gorohovski</surname><given-names>A.</given-names></name><name><surname>Lacroix</surname><given-names>V.</given-names></name><name><surname>Rogers</surname><given-names>M.</given-names></name><name><surname>Ibanez</surname><given-names>K.</given-names></name><name><surname>Boullosa</surname><given-names>C.</given-names></name><name><surname>Andres&#x000a0;Leon</surname><given-names>E.</given-names></name><name><surname>Ben-hur</surname><given-names>A.</given-names></name><name><surname>Valencia</surname><given-names>A.</given-names></name><name><surname>Leon</surname><given-names>E.A.</given-names></name><etal/></person-group>
<article-title>ChiTaRS: a database of human, mouse and fruit fly chimeric transcripts and RNA-sequencing data</article-title>
<source>Nucleic Acids Res.</source>
<year>2013</year>
<volume>41</volume>
<fpage>D142</fpage><lpage>D151</lpage><pub-id pub-id-type="pmid">23143107</pub-id></element-citation></ref><ref id="B184"><label>184.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frenkel-Morgenstern</surname><given-names>M.</given-names></name><name><surname>Gorohovski</surname><given-names>A.</given-names></name><name><surname>Vucenovic</surname><given-names>D.</given-names></name><name><surname>Maestre</surname><given-names>L.</given-names></name><name><surname>Valencia</surname><given-names>A.</given-names></name></person-group>
<article-title>ChiTaRS 2.1-an improved database of the chimeric transcripts and RNA-seq data with novel sense-antisense chimeric RNA transcripts</article-title>
<source>Nucleic Acids Res.</source>
<year>2014</year>
<volume>43</volume>
<fpage>68</fpage><lpage>75</lpage></element-citation></ref><ref id="B185"><label>185.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonda</surname><given-names>T.J.</given-names></name><name><surname>Ramsay</surname><given-names>R.G.</given-names></name></person-group>
<article-title>Directly targeting transcriptional dysregulation in cancer</article-title>
<source>Nat. Rev. Cancer</source>
<year>2015</year>
<volume>15</volume>
<fpage>686</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">26493648</pub-id></element-citation></ref><ref id="B186"><label>186.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Montenegro</surname><given-names>M.F.</given-names></name><name><surname>S&#x000e1;nchez-del-Campo</surname><given-names>L.</given-names></name><name><surname>Fern&#x000e1;ndez-P&#x000e9;rez</surname><given-names>M.P.</given-names></name><name><surname>S&#x000e1;ez-Ayala</surname><given-names>M.</given-names></name><name><surname>Cabezas-Herrera</surname><given-names>J.</given-names></name><name><surname>Rodr&#x000ed;guez-L&#x000f3;pez</surname><given-names>J.N.</given-names></name></person-group>
<article-title>Targeting the epigenetic machinery of cancer cells</article-title>
<source>Oncogene</source>
<year>2015</year>
<volume>34</volume>
<fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">24469033</pub-id></element-citation></ref><ref id="B187"><label>187.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bondeson</surname><given-names>D.P.</given-names></name><name><surname>Mares</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>I.E.D.</given-names></name><name><surname>Ko</surname><given-names>E.</given-names></name><name><surname>Campos</surname><given-names>S.</given-names></name><name><surname>Miah</surname><given-names>A.H.</given-names></name><name><surname>Mulholland</surname><given-names>K.E.</given-names></name><name><surname>Routly</surname><given-names>N.</given-names></name><name><surname>Buckley</surname><given-names>D.L.</given-names></name><name><surname>Gustafson</surname><given-names>J.L.</given-names></name><etal/></person-group>
<article-title>Catalytic in vivo protein knockdown by small-molecule PROTACs</article-title>
<source>Nat. Chem. Biol.</source>
<year>2015</year>
<volume>11</volume>
<fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">26075522</pub-id></element-citation></ref><ref id="B188"><label>188.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winter</surname><given-names>G.E.</given-names></name><name><surname>Buckley</surname><given-names>D.L.</given-names></name><name><surname>Paulk</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>J.M.</given-names></name><name><surname>Souza</surname><given-names>A.</given-names></name><name><surname>Dhe-Paganon</surname><given-names>S.</given-names></name><name><surname>Bradner</surname><given-names>J.E.</given-names></name></person-group>
<article-title>Phthalimide conjugation as a strategy for in vivo target protein degradation</article-title>
<source>Science</source>
<year>2015</year>
<volume>348</volume>
<fpage>1376</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">25999370</pub-id></element-citation></ref></ref-list></back></article>